Protocol : ID-[ADDRESS_504492] -246475 in Adults With Stable Coronary Artery Disease  
ClinicalTrials.gov  Identifier: [STUDY_ID_REMOVED]  
ACT- [ADDRESS_504493] -246475 in adults with stable coronary artery disease  
Study Ph
ase: [ADDRESS_504494] Number: 2017-003332-36 
Status and version: Version  1 
Date:  [ADDRESS_504495] 2017 
Document type: Global Protocol 
Idorsia  document number (Doc No.):  D-17.[ADDRESS_504496] 2017, page 2/[ADDRESS_504497] DETAILS 
Sponsor  Idorsia  Pharmaceuticals Ltd  
Hegenheimermattweg 91  
CH-4123 Allschwil 
Switzerland  
ï€¨ [PHONE_744] [ADDRESS_504498] details of the Clinical Trial Physician can 
be found in the Investigator Site File . 
Medical Emergency Hotline  
Toll phone number:  Site-specific toll telephone numbers and toll -free 
numbers for the Medical Emergency Hotline can 
be found in the Investigator Site File . 
SPONSOR CONTRIBUTORS TO THE PROTOCOL 
Clinical Trial Scientist   
Clinical Trial Statistician   
Clinical Trial Physician   
Clinical Trial Pharmacologist  
Drug Safety Physician   
COORDINATING INVESTIGATOR 
[CONTACT_5627] / Title  Address  
 Department of Infection, Immunity & 
Cardiovascular Disease  
University of Sheffield  
 
 
Sheffield  
S10 2RX  [LOCATION_006] 
CONTRACT RESEARCH ORGANIZATIONSâ€™ INFORMATION 
Some activities will be delegated to Contract Research Organizations ( CROs ). A list of 
site-specific contact [CONTACT_42886].  

$&7
&RURQDU\DUWHU\GLVHDVH
3URWRFRO,'$
9HUVLRQ
$XJXVWSDJH&RQILGHQWLDO(XGUD&7
'RF1R'
6,*1$785(3$*()25,'256,$3+$50$&(87,&$/6/7'
+HUHLQDIWHUFDOOHGWKHVSRQVRU
6WXG\WLWOH
$ PXOWLFHQWHU GRXEOHEOLQG UD QGRPL]HG SODFHERFRQWUROOHG VW XG\ WR DVVHVV WKH
SKDUPDFRG\QDPLFVSKDUPDFRNLQHWLFVWROHUDELOLW\DQGVDIHW\RI DVLQJOHVXEFXWDQHRXV
LQMHFWLRQRI$&7LQDGXOWVZ LWKVWDEOHFRURQDU\DUWHU\G LVHDVH
,DSSURYHWKHWHUPVDQGFRQGLWLRQVUHODWLQJWRWKLVVWXG\DVGH ILQHGLQWKLVSURWRFRO,
FRQILUPWKDWWKHLQIRUPDWLRQFRQW DLQHGLQWKLVSURWRFROLVFRQV LVWHQWZLWKWKHFXUUHQW
ULVNEHQHILWHYDOXDWLRQRI$&7DQGZLWKWKHHWKLFDODQG VFLHQWLILFSULQFLSOHV
JRYHUQLQJFOLQLFDOUHVHDUFKDVVHWRXWLQWKH'HFODUDWLRQRI+H OVLQNLDQGWKH,QWHUQDWLRQDO
&RXQFLOIRU+DUPRQLVDWLRQ,&+*RRG&OLQLFDO3UDFWLFH*&3JX LGHOLQHV

ACT -[ADDRESS_504499] 2017, page 4/[ADDRESS_504500]-246475 in adults with stable coronary artery disease  
I agree to the terms and conditions relating to this study as defined in this protocol and any other protocol -related documents. I fully understand that any changes instituted by 
[CONTACT_093](s) without previous agreement with the sponsor would constitute a protocol deviation, including any ancillary studies or procedures performed on study 
subjects (other than those procedures necessary for the wellbeing of the subjects). 
I agree to conduct this study in accordance with the Declaration of Helsinki principles, 
Interna tional Council for Harmonisation (ICH) Good Clinical Practice (GCP) guidelines, 
and applicable regulations and laws. 
Principal 
Investigator  

[INVESTIGATOR_215152] -[ADDRESS_504501] 2017, page 5/[ADDRESS_504502] RESEARCH OR GANIZATIONSâ€™ INFORMATION  ..................................[ADDRESS_504503] OF ABBREVIATION S AND ACRONYMS  ..........................................................11  
PROTOCOL SYNOPSIS ID-076A201 .............................................................................14  
1 BACKGROUN D .........................................................................................................23  
1.1 Pre-hospi[INVESTIGATOR_400368]  .................................23  
1.2 Role of adenosine diphosphate-induced platelet activation (P2Y 12 
receptor)  ........................................................................................................23  
1.3 Study treatment (ACT -246475) ....................................................................25  
1.3.1  Nonclinical data  ................................................................................25  
1.3.2  Effects in humans ..............................................................................26  
[IP_ADDRESS]  Study AC -075-101 ..................................................................26  
[IP_ADDRESS]  Study AC -076-101 ..................................................................26  
[IP_ADDRESS]  Study AC -076-[ADDRESS_504504] 2017, page 6/[ADDRESS_504505] population description .....................................................................35  
4.2 Rationale for the selection of the study population ......................................35  
4.3 Inclusion criteria  ...........................................................................................36  
4.4 Exclusion criteria  ..........................................................................................36  
4.5 Criteria for women of childbearing potential ...............................................38  
4.5.1  Definition of childbearing potential ..................................................38  
4.5.2  Acceptable methods of contraception ...............................................38  
5 TREATMENTS  ..........................................................................................................38  
5.1 Study treatment  .............................................................................................38  
5.1.1  Investigational treatment and matching placebo: Description 
and rationale ......................................................................................38  
5.1.2  Study t reatment supply .....................................................................39  
[IP_ADDRESS]  Study treatment packaging and labeling  .................................39  
[IP_ADDRESS]  Study treatment distribution and storage .................................39  
[IP_ADDRESS]  Study treatment return and destruction ...................................40  
5.1.3  Study treatment assignment and dispensing .....................................41  
[IP_ADDRESS]  Study treatment assignment  .....................................................41  
[IP_ADDRESS]  Study treatment dispensing .....................................................41  
5.1.4  Study treatment preparation and administration  ...............................41  
5.1.5  Blinding ............................................................................................42  
5.1.6  Unblinding ........................................................................................43  
[IP_ADDRESS]  Unblinding for final analyses ..................................................43  
[IP_ADDRESS]  Unblinding for interim analyses ..............................................43  
[IP_ADDRESS]  Unblinding for suspected unexpected serious adverse reactions  ...................................................................................43
 
[IP_ADDRESS]  Emergency procedure for unblinding ......................................43  
5.1.7  Study treatment accountability and compliance with study treatment  ...........................................................................................44
 
[IP_ADDRESS]  Study treatme nt accountability ................................................44  
[IP_ADDRESS]  Study treatment compliance  ....................................................44  
5.1.8  Study treatment dose adjustments and interruptions ........................44  
5.1.9  Premature discontinuation of study treatment  ..................................44  
5.1.10  Study- specific criteria for interruption / premature 
discontinuation of study treatment ....................................................[ADDRESS_504506] 2017, page 7/[ADDRESS_504507] 2017- 003332- 36 
Doc No D-17.029  
5.2 Previous and concomitant therapy  ................................................................44  
5.2.1  Definitions  ........................................................................................44  
5.2.2  Reporting of previous/concomitant therapy in the case report 
form  ...................................................................................................45  
5.2.3  Allowed concomitant therapy ...........................................................45  
5.2.4  Forbidden concomitant therapy ........................................................45  
6 STUDY ENDPOINTS  ................................................................................................45  
6.1 Efficacy endpoints ........................................................................................45  
6.2 Pharmacokinetic and pharmacodynamic endpoints .....................................46  
6.2.1  Pharmacodynamic endpoints  ............................................................46  
6.2.2  Pharmacokinetic endpoints ...............................................................46  
6.3 Safety endpoints  ...........................................................................................46  
7 VISIT SCHEDULE AND STUDY ASSESSMENTS  ................................................46  
7.1 Study visits  ...................................................................................................46  
7.1.1  Screening/re -screening  ......................................................................47  
7.1.2  Unscheduled visits ............................................................................47  
7.2 Study assessments  .........................................................................................50  
7.2.1  Demographics / baseline characteristics  ...........................................50  
7.2.2  Efficacy assessments  .........................................................................51  
7.2.3  Pharmacokinetic and pharmacodynamic assessments  ......................51  
[IP_ADDRESS]  Pharmacodynamic assessments  ...............................................51  
[IP_ADDRESS]  Pharmacokinetic assessments  ..................................................52  
7.2.4  Safety assessments  ............................................................................53  
[IP_ADDRESS]  Physical examination  ...............................................................53  
[IP_ADDRESS]  Vital signs  ................................................................................53  
[IP_ADDRESS]  Weight and height ...................................................................53  
[IP_ADDRESS]  ECG assessment  ......................................................................53  
7.2.5  Laboratory assessments  ....................................................................54  
[IP_ADDRESS]  Type of laboratory ...................................................................54  
[IP_ADDRESS]  Laboratory tests  .......................................................................[ADDRESS_504508] -STUDY TREATMENT / MEDICAL 
CARE  ..........................................................................................................................56  
8.1 Study completion  ..........................................................................................56  
8.2 Premature withdrawal from study  ................................................................56  
8.3 Premature termination or suspension of the study ........................................57  
8.4 Medical care of subjects after study completion / withdrawal from study ..............................................................................................................[ADDRESS_504509] 2017, page 8/[ADDRESS_504510] 2017- 003332- 36 
Doc No D-17.029  
9 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS  ...........................57  
9.1 Adverse events  ..............................................................................................57  
9.1.1  Definition of adverse events .............................................................57  
9.1.2  Intensity of adverse events  ................................................................58  
9.1.3  Relationship to study treatment ........................................................59  
9.1.4  Reporting of adverse events ..............................................................59  
9.1.5  Follow-up of adverse events .............................................................59  
9.2 Serious adverse events  ..................................................................................59  
9.2.1  Definitions of serious adverse events ...............................................59  
9.2.2  Reporting of serious adverse events .................................................60  
9.2.3  Follow-up of serious adverse events .................................................61  
9.2.4  After the 30 -day follow-up period ....................................................61  
9.3 Pregnancy  .....................................................................................................61  
9.3.1  Reporting of pregnancy ....................................................................61  
9.3.2  Follow-up of pregnancy ....................................................................62  
9.4 Study safety monitoring  ................................................................................62  
10 STATISTICAL METHODS  .......................................................................................62  
10.1  Analysis sets  .................................................................................................62  
10.1.1  Screened analysis set  ........................................................................62  
10.1.2  Randomized analysis set  ...................................................................62  
10.1.3  Full analysis set  .................................................................................62  
10.1.4  Per-protocol analysis set  ...................................................................63  
10.1.5  Safety set  ...........................................................................................63  
10.1.6  Pharmacokinetic analysis set  ............................................................63  
10.1.7  Usage of the analysis sets  .................................................................63  
10.2  Variables  .......................................................................................................64  
10.2.1  Primary efficacy variable(s)  ..............................................................64  
10.2.2  Key secondary efficacy variables  .....................................................64  
10.2.3  Safety variables  .................................................................................64  
[IP_ADDRESS]  Adverse events  ........................................................................64  
[IP_ADDRESS]  Laboratory data  ........................................................................65  
[IP_ADDRESS]  ECG  .........................................................................................65  
[IP_ADDRESS]  Vital signs  ................................................................................65  
10.2.4  Pharmacokinetic and pharmacodynamic variables  ...........................65  
[IP_ADDRESS]  Pharmacokinetic variables  .......................................................65  
[IP_ADDRESS]  Pharmacodynamic variables  ....................................................[ADDRESS_504511] 2017, page 9/[ADDRESS_504512] 2017- 003332- 36 
Doc No D-17.029  
[IP_ADDRESS]  Hypotheses and statistical model ............................................67  
[IP_ADDRESS]  Handli ng of missing data  .........................................................68  
[IP_ADDRESS]  Main analysis  ...........................................................................68  
[IP_ADDRESS]  Supportive/sensitivity analyses ...............................................69  
10.3.3  Analysis of key secondary efficacy variable(s)  ................................69  
10.3.4  Analysis of the safety variables  ........................................................69  
[IP_ADDRESS]  Adverse events  ........................................................................69  
[IP_ADDRESS]  Laboratory data  ........................................................................70  
[IP_ADDRESS]  Vital signs, weight and physical examination  .........................70  
[IP_ADDRESS]  Electrocardiograms  ..................................................................70  
10.4  Interim analyses  ............................................................................................70  
10.5  Sample size  ...................................................................................................70  
11 DATA HANDLING  ....................................................................................................71  
11.1  Data collection  ..............................................................................................71  
11.2  Maintenance of data confidentiality  .............................................................72  
11.3  Database management and quality control  ...................................................72  
12 PROCEDURES AND GOOD CLINICAL PRACTICE  .............................................73  
12.1  Ethics and Good Clinical Practice  ................................................................73  
12.2  Independent Ethics Committee / Institutional Review Board  ......................73  
12.3  Informed  consent ..........................................................................................74  
12.4  Compensation to subjects and investigators .................................................75  
12.5  Protocol adherence/compliance  ....................................................................[ADDRESS_504513] 2017, page 10/[ADDRESS_504514] 2017, page 11/[ADDRESS_504515] OF ABBREVIATIONS AND ACRONYMS 
ACS  Acute cor onary syndrome 
ADP  Adenosine di
phosphate 
AE Adverse 
event  
AMI  Acute myocardial infarction  
AUC  Area und er the plasma concentration -time curve  
AUC 0â€“24h Area under the plasma concentration -time cu rve from  time zero to 
24 h time point 
BP Blood pressure  
CAD  Coronary artery disease  
CFR  Code of  Federal Regulations (US)  
CI Confid
ence interval  
Cmax Maximum plasma concentr ation 
CRA  Clinical
 research associate 
CRF  (Electronic ) case report form  
CRO  Contract  Research Organization  
CSR  Clinical s
tudy report  
CTT Clinical tr
ial team 
CV Coefficient of variation  
CYP  Cytochr ome P450 
DAPT  Dual an
tiplatelet therapy  
ECG  Electroc
ardiogram  
EDTA  Ethylened
iaminetet raacetic acid  
eGFR  Estimated glomerular filtration rate  
EOS  End-of-St udy 
FAS Full analy
sis set 
g Gravita
tional constant 
GCP  Good C
linical Practice  
HA Health authorit y 
i.v. Intravenous (ly) 
IB Investigatorâ€™ s Broc hure 
ACT -[ADDRESS_504516] 2017, page 12/[ADDRESS_504517]  
IRT Interac
tive Response Technology 
ISF Investig
ator Site File  
LTA  Light transmission aggregometry  
MedDRA  Medical Dictionary for Regulatory Activities  
MI Myocar
dial infarction  
MTD  Maximum to
lerated dose  
OATP  Organic anion -transporting polypeptide  
PCI Percutaneous coronary intervention  
PD Pharmacodynamic(s)  
PI [INVESTIGATOR_400369]
l Investigator  
PK Pharmacok
inetic(s)  
PPACK  Phenylalan
ine-proline-arginine-chloromethyl ketone 
PPS Per-protocol set 
PRP Platelet -ric h plasma  
PRU  P2Y 12 reaction units 
QA (Sponsor) Q
uality Assurance 
QS (Sponsor) Q
uality System 
QTcB  QT corrected with Bazettâ€™s formula  
QTcF  QT cor rected with Fridericiaâ€™s formula  
RND Randomi
zed analysis set  
RSI Reference s
afety information  
s.c. Subcutaneous  
s.l. Sublingual  
SAD Single -as cending dose 
SAE  Serious
 adverse event  
ACT -[ADDRESS_504518] 2017, page 13/[ADDRESS_504519] 2017, page 14/[ADDRESS_504520] -246475 in adults with stable coronary artery disease. 
OBJECTIVES  Primary objective(s)  
The primary objective of the study is to characterize inhibition 
of platelet aggregation  (IPA) relatively to placebo after a single 
subcutaneous ( s.c.) injection of ACT -246475 either in the thigh 
or in the abdomen at 2 different doses in subjects with stable 
coronary artery disease ( CAD) receiving conventional 
background oral  antiplatelet therapy (e.g., acetylsalicylic acid, 
P2Y 12 receptor antagonists). 
Other objectives  
The other objectives of this study are described in Section 2.2.  
DESIGN  This is a prospective, multi -national, multi -center, double -blind, 
randomized, placebo- controlled, parallel -group, Phase  2, 
exploratory study  of a single s.c. administration of ACT -246475, 
at 2 different dose levels,  in subjects with stable CAD receiving 
conventional background therapy (e.g., acetylsalicylic acid, 
P2Y 12 receptor antagonists, etc. ). 
Approximately 324 adult s ubjects with stable CAD will be 
randomized into  1 of the 8 combinations of the treatment, dose, 
and injection site using a 2:2:2:2:1:1:1:1 ratio:  
ACT -[ADDRESS_504521] 2017, page 15/[ADDRESS_504522] -246475 or matchi ng placebo, 
either in the thigh or in the abdomen. 
Double- blinding will apply to treatment (ACT -246475 vs 
placebo). The dose (8 mg vs 16 mg) will be single blinded 
(subject blinded). The injection site (thigh vs abdomen) will not 
be blinded. 
Treatment group allocation will be stratified based on baseline 
platelet reactivity value (expressed as P2Y 12 reaction units  
[PRU ]) measured on Day 1 by [CONTACT_400395]Â® assay before 
ACT -246475 injection considering the 3 following categories: 
high reactivit y (PRU  > 250), medium reactivity 
(150 â‰¤ PRU  â‰¤ 250), and low reactivity (PRU < 150). 
The study comprises the following consecutive periods: 
Screening period:  Lasts 1 to 21 days; starts with the signature 
[CONTACT_400436] âˆ’ 1. 
Trea tment period:  Lasts 2 days: Day 1 and Day 2. 
Follow- up period:  Lasts [ADDRESS_504523] 2017, page 16/[ADDRESS_504524] 2017- 003332- 36 
Doc No D-17.029  
SITE(S)  
/ COUNTRY(IES)  Approximately 20 sites in 5 â€“10 countries are planned.  
INCLUSION CRITERIA  1. Signed  informed consent prior to any study -mandated
procedure.
2. Male and female subjects aged from 18 â€“85 years,
inclusive.
3. For women of childbearing potential: Negative urine
pregnancy test at Visit 1 and at Visit 2 before
randomization.
4. Stable CAD defined by [CONTACT_400396]:
a.History of CAD  with coronary artery stenosis on coronary
angiogram â‰¥  50%.
b.Previously documented myocardial infarction  occurring
more than [ADDRESS_504525]
1 month prior to randomization.
6. Body weight â‰¥ 40.0 kg (88.2 lbs).
EXCLUSION CRITERIA  Conditions associated with atherosclerosis:  
1.Acute coronary syndrome , percutaneous coronary
intervention or any intervention for peripheral artery disease
within 3 months prior to randomization.
2.Acute ischemic stroke or transient ischemic attack within
3 months prior to randomization.
Mitigation of bleeding risks:  
3.Active internal bleeding, or medical history of recent
(< 1 month) bleeding disorders or conditions associated with
high risk of bleeding (e.g., clotting disturbances,
gastrointestinal bleed, hemoptysis).
4. Hemoglobin â‰¤ 10 g/dL at screening.
5.Loss of at least 250 mL of blood within 3 months of
screening.
6.Use of anticoagulants ( oral, parenteral) or fibrinolytic
therapy within 24 h prior to screening (Visit 1).
7.Known  platelet disorders (e.g., thrombasthenia,
thrombocytopenia, von Willebrand disea se).
ACT -[ADDRESS_504526] 2017, page 17/[ADDRESS_504527] from complying with 
study requirements or may be a confounder for the study 
interpretation:  
8.Pregnant or breastfeeding women.
9.Uncontrolled hypertension according to investigator â€™s
judgment.
10.Known and documented moder ate or severe hepatic
impairment.
11.End-stage renal failure requiring dialysis.
12.Any clinically significant findings on a physical exam, or
laboratory tests prior to screening that in the investigator â€™s
judgment would preclude safe or reliable participation of a
subject in the study.
13.Concomitant diseases (e.g., advanced liver cirrhosis, mentalillness, neurodegenerative disease, terminal malignancy ,
etc.) or conditions (e.g., inability to communicate well with
the investigator in the local language) that, in the opi[INVESTIGATOR_277392], may prevent subject from complying with
study requirements or may be a confounder for the study
interpretation.
14.Veins unsuitable for intravenous puncture on either arm
(e.g., difficult to locate, access, or puncture) accordi ng to the
investigator â€™s judgment.
15.Clinically relevant skin disease that prevents s.c. injection in
the thigh or abdomen, according to the investigator â€™s
judgment.
16.Use of inhibitors of organic anion- transporting polypeptide
(OATP )1B1 or OATP1B3 at screening (Visit 1).
17.Known hypersensitivity to ACT -246475, any of its
excipi[INVESTIGATOR_840], or drugs of the P2Y12 class.
18.Previous exposure to investigational drug within 3 monthsprior to screening.
STUDY TREATMENTS Investigational treatment  and matching placebo  
Study treatment for s.c. administration will be available as 
sealed glass vials in 1 strength: [ADDRESS_504528] -246475A (hydrochloride salt of 
ACT -246475) or matching placebo  to be reconstituted with 
ACT -[ADDRESS_504529] 2017, page 18/[ADDRESS_504530] 2017- 003332- 36 
Doc No D-17.029  
1 mL of water for injec tion. Further dilution with 1 mL NaCl 
0.9% will be performed for preparation of the dose of [ADDRESS_504531] -246475 
(8 or 16 mg) or of matching placebo in a volume of 0.8 mL , 
administered s.c. at site by [CONTACT_5944] (e.g., nurse, 
physician).  
The investigational treatment and its matching placebo are 
indistinguishable, and all treatment kits will be packaged in the 
same way.  
CONCOMITANT 
THERA PY Allowed concomitant therapy  
Unless medically necessary, subjects will continue their standard 
treatment(s) (including oral P2Y 12 receptor antagonists and 
acetylsalicylic acid) as prescribed (treatments and doses), from Visit 1 (screening) and up to the last PK or PD  blood sample 
collection  (whichever is latest) . 
Forbidden concomitant therapy  
The following medications are prohibited from screening and up to last pharmacokinetic ( PK) or pharmacodynamic ( PD) blood 
collection (whichever is latest):  
â€¢Fibrinolytic therapy (e.g., streptokinase, alteplase, etc. )
â€¢Anticoagulants (e.g., Coumadin, warfarin, anti Xa inhibitors,
dabigatran, heparin)
â€¢OATP1B1 and OATP1B3 inhibitors (e.g., cyclosporine,
eltrombopag, lapatinib, lopi[INVESTIGATOR_054], rifampin, ritonavir)
Initiation of any of the following medications is prohibited from screening up to last PK or PD blood collection (whichever is 
latest): 
â€¢Oral P2Y
12 receptor antagonists (e.g., clopi[INVESTIGATOR_7745], prasugrel,
ticagrelor)
â€¢Cangrelor
ACT -[ADDRESS_504532] 2017, page 19/[ADDRESS_504533] 2017- 003332- 36 
Doc No D-17.029  
ENDPOINTS Primary efficacy endpoin t(s) 
Not applicable 
Pharmacodynamic endpoints  
The primary PD endpoint is the PD response that is defined for 
each subject as a PRU < [ADDRESS_504534] 3 hours, as measured via the VerifyNow
Â® 
assay. This corresponds to inhibition of adenosine 
diphosphate-induced platelet aggregation (IPA) > 80%. 
Safety endpoints  
The safety endpoints will be assessed up to End- of-Study:  
â€¢Treatment -emergent adverse events  (AEs)  and serious AEs
(SAEs).
â€¢All AEs and S AEs.
â€¢Change in vital signs (systolic and diastolic arterial blood
pressure and pulse rate) from baseline to all assessed time
points during the study.
â€¢Treatment -emergent ECG  abnormalities.
â€¢Change from baseline to each measured time point in ECG
variables: heart rate and the intervals: PQ/ PR, QRS, QT, RR,
QT corrected with Bazett â€™s formula , QT corrected with
Fridericiaâ€™ s formula .
â€¢Change from baseline to each measured time point for
clinical laboratory tests.
â€¢Treatment -emergent marked laboratory abnorma lities.
Pharmacokinetic  endpoints  
PK endpoints are described in Section 6.2.2. 
ASSESSMENTS Refer to the schedule of assessments in  Table [ADDRESS_504535] 
been assigned to a double blind study treatment. 
The Full analysis set  (FAS)  includes all randomized subjects 
ACT -[ADDRESS_504536] 2017, page 20/[ADDRESS_504537] been administered the study treatment. 
The Per -protocol set i ncludes all FAS subjects who complied 
with protocol sufficiently to allow adequate estimation of the 
treatment effects  (criteria for sufficient compliance will be 
detailed in the statistical analysis plan ). 
The Safety set  includes all subjects w ho received at least [ADDRESS_504538] at type I error level of 0.025 (corresponding to an
overall level of 0.05 adjusted for multiplicity through Bonfer roni
method). For each active treatment arm  for which comparison to
placebo is st atistically significant, the hy pothesis that a
proportion of patients achieving a response  is greater than 70%
will be tested at a 0.[ADDRESS_504539], from 
start of treatment up to 8 h a fter injection, on platelet reactivity 
as measured by [CONTACT_87253]Â®, i.e., PRU value, will be performed 
using a mixed model with PRU as dependent variable, subject as 
random factor, and treatment (8 mg, 16 mg, and placebo), 
injection site (abdomen, thigh), PR U level at randomization 
(stratification levels), age (continuous), gender (male, female), 
and assessment time (continuous) as fixed factors. The model 
will also include (treatment Ã— injection site)  as an interaction 
term to assess consistency of treatment  effect across injection 
sites.  
A logistic regression analysis of the PD response will be 
performed using the same factor s as covariates.  
ACT -[ADDRESS_504540] 2017, page 21/[ADDRESS_504541] 2017- 003332- 36 
Doc No D-17.029  
Summary of PD response, in term s of number (%) of subjects, 
will be provided. IPA as measured by [CONTACT_87253]Â® will also be 
summarized as a continuous variable. 
Supportive/sensitivity analyses 
Consistency across the following subgroups will be assessed by 
[CONTACT_400397], assuming relevant 
number of subjects: 
â€¢Age: < 55 vs â‰¥ 55 years
â€¢Body ma ss index: < 25.0 vs (â‰¥ 25.0 and < 30.0)
vs â‰¥ 30.0 kg/m2
â€¢Sex: mal
e vs female
â€¢Diabetes mellitus at baseline: yes vs no
â€¢Chronic kidney disease: yes vs no
Additional analyses of  the supportive PD endpoint ( light 
transmission aggregometry -based PD response) wi ll be 
conducted using the same approach as described for the primary 
PD analysis.  
Sample size  
The primary objective is to assess the effectiveness of 
ACT -246475 to allow subjects to achieve a predefined PD 
response; therefore , the sample size provided is sufficient  to 
sequentially demonstrate that at least [ADDRESS_504542] -246475 
doses has a higher response rate than placebo and that this 
response rate is greater than 70%.  
The sample size required for demonstrating a difference to placebo, based on an overall type I error of 0.05 (2-sided), adjusted for multiplicity using a Bonfer roni method to 0.025 for 
each comparison, a power of 90%, a response rate of 50% under H
0 (placebo) and 75% under H 1 is 96 per arm. 
The sample size required to demonstrate that the response rate is different from 70% is based on a 2- sided type I error of 0.025, a 
power of 90%; and the assumptions of a response rate of 70% 
under H
0 and 85% under H [ADDRESS_504543] 2017, page 22/[ADDRESS_504544] 2017- 003332- 36 
Doc No D-17.029  
about 10%, [ADDRESS_504545] 2017, page 23/[ADDRESS_504546] ion (AMI ) in the past decades, there is still a medical need for an 
earlier treatment option to reduce high platelet reactivity, once a secondary event occurs 
[Nabel  2012] . The median time to medical intervention in economically advanced 
countries, either in an ambulance or at the emergency department , is still 2â€“4 hours after 
onset of symptoms , with patient decision time contr
ibuting significantly to the 
pre-hospi[INVESTIGATOR_400370]  [Garofalo  2012, Tubaro 2011].  
Patients experiencing an AMI have highly reactive platelets, whi ch are insufficiently 
inhibited  even when they are receiving dual antiplatelet therapy
 (DAPT) with 
acetylsalicylic acid and clopi[INVESTIGATOR_7745] [Gurbel 2003; Matetzky  2004; Wang  2010] . 
The earlier one intervenes on the ongoing platelet -rich thrombus responsible for AMI , the 
higher the chance to avoid early death an
d irreversible myocardial damage. The first 
1â€“3 hours 
after symptom onset (â€˜golden time â€™) hold the maximum potential for 
myocardial reperfusion and salvage in patients with ST-segment elevation myocardial 
infarction ( STEMI ) [Savonitto 2017] . Hence, shortening the time to treatment could be of 
therapeutic benefit.  The European Society of Cardiology guidelines recommend 
ticagrelor and prasugrel as a first -line a
ntiplatelet therapy on top of acetylsalicylic acid  in 
AMI ; however , evidence of their benefit in the pre- hospi[INVESTIGATOR_400371] 
[Beygui 2015] . 
ACT -246475 is  being developed for self-injection in patients with suspected AMI . 
1.2 Role of adenosine diphosphate-induced platelet activation (P2Y 12 
receptor)  
When vascular integrity is compromi sed, signals are generated that cause circulating 
platelets to adhere to the vessel wall, become activated, and aggregate, forming a plug that seals off the site of injury to prevent blood loss. Autopsy studies demonstrated that the same processes occur up on rupture of an atherosclerotic plaque and can lead to 
uncontrolled platelet thrombus formation and vessel occlusion [Davies  1986] . Inhibition 
of platele t activation and aggregation is recognized as an effective strategy for prevention 
of atherothrombotic events i 
n patients with atherosclerotic disease in the coronary, 
peripheral, and cerebrovascular circulation [ DavÃ¬  2007, Michelson  2010].  
The adenosine diphosphate (ADP) receptor P2Y 12 plays a critical role in platelet 
activation and aggregation [Andre 2003, Dorsam  2004] . Platelet activation is initially 
ACT -[ADDRESS_504547] 2017, page 24/[ADDRESS_504548] at two G protein -coupled receptors, P2Y
1 and 
P2Y 12. Both P2Y 1 and P2Y 12 participate in the activation of integrin glycoprotein IIb/IIIa, 
which binds fibrinogen, creating the cross -linked aggregates that form the thrombus. 
Whereas P2Y [ADDRESS_504549] is recommended [Oâ€™Gara 2013, 
Amsterdam  2014] . The efficacy of clopi[INVESTIGATOR_7745], the most widely used P2Y [ADDRESS_504550] prasugrel achieves more pronounced 
inhibition of platelet aggregation  (IPA)  and shows superior efficacy compared with 
clopi[INVESTIGATOR_7745], but the reduced risk of ischemic events is accompanied by [CONTACT_400398] [Wiviott 2007] . The need to reduce bleeding risk is illustrated by [CONTACT_447] -hoc 
analyses of several anti -platelet clinical studies [Eikelboom 2006, Amlani 2010] . These 
analyses revealed that there is a 
strong association between major bleeding and mortality 
in AMI patients.  
P2Y 12 receptor antagonists from the thienopyridine class, such as clopi[INVESTIGATOR_400372], are prodrugs converted to active metabolites that irreversibly bind and inactivate the P2Y
12 receptor for the lifespan of the platelet. It was initially thought that 
antagonists that bind reversibly to the receptor, such as ticagrelor, are less likely to cause bleeding than those that cause irreversible blockade, possibly because receptors remain  
responsive to high local concentrations of ADP [van Giezen  2009, Becker  2010] . In the 
PLATO trial, ticagrelor demonstrated a significant reduction in the risk of de 
ath from 
vascular cau
ses / myocardial infarction  (MI)  / stroke, without a significant increase in 
PLATO -defined major bleeding compared to clopi[INVESTIGATOR_7745] [Wallentin  2009] . However, 
ticagrelor still significantly increased major bleeding not associated with coronary artery 
by[CONTACT_400399] [Wallentin  2009, Husted  2011] . Therefore, novel principles of P2Y 12 
antagonism are needed with the potential to improve efficacy without adversely affecting safety.  
Some of the bleeding associated with current P2Y
12 receptor antagonists may be due to 
off-target effects. In a study comparing clopi[INVESTIGATOR_400373] P2Y 12 receptor in mice, the thienopyridines caused excess bleeding and had adverse 
effects  on vascular tone [Andre 2011] . In-house nonclinical studies indicate that 
ticagrelor, but not ACT -246475, inhibits vasoconstriction in isolated vessels 
ACT -[ADDRESS_504551] 2017, page 25/[ADDRESS_504552] 2017 -003332 -36 
Doc No D-17.029  
[ACT -246475 IB]. After vessel injury, vasoconstriction is essential to achieve hemostasis 
and subsequent wound sealing. Theref
ore, a highly selective P2Y [ADDRESS_504553] 
has the potential to provide an improved therapeutic window compared with current 
P2Y 12 receptor antagonists. 
1.3 Study treatment  (ACT-246475) 
ACT -[ADDRESS_504554] 
with rapid onset and a short duration of action, suitable for subcutaneous ( s.c.) 
administration. Efficacy and safety studies with ACT -[ADDRESS_504555] -246475 is considered as a promising n ew 
 agent for secondary prevention of major 
adverse cardio vascular events in patients with suspected AMI , including those 
undergoing percutaneous coronary intervention (PCI) . 
1.3.[ADDRESS_504556] -246475 to the receptor is fully reversible, with an equilibrium dissociation constant 
of 1.5 nM. In human platelet -rich plasma (PRP), ACT -246475 inhibited ADP -induced 
platelet aggregation with an inhibitor concentra tion causing 50% inhibition of 8.7 ng/mL 
(14 nM). 
ACT -[ADDRESS_504557] -246475, caused relaxation of precontracted arteries and 
inhibited vasoconstriction induced by [CONTACT_400400] 
(Î±1-adrenoceptor -mediated). The absence of effect on vascular tone explains, at least in 
part, the reduction in bleeding with ACT-246475. 
   
  
 
  
 

ACT -[ADDRESS_504558] 2017, page 26/[ADDRESS_504559] -246475 has low potential for drug- drug interaction with co -medications dependent 
on cytochrome P450 (CYP) metabolism. ACT -[ADDRESS_504560] -246475.  
 
 
. 
 
Detailed
 information regarding nonclinical data is available in the Investigator â€™s 
Brochure  (IB)  [ACT -246475 IB]. 
1.3.[ADDRESS_504561] been comp
leted to date (AC -075- 101, AC -076- 101). Another 
trial is clinically completed
 with preliminary data available (AC -076-102). Results of 
these studies  are detailed in the IB [ACT -246475 IB] and summarized hereafter . 
[IP_ADDRESS] Study AC -075-
101 
This study consisted of 2 p
arts: 
In Pa
rt I, the safety, tolerability, pharmacokinetics ( PK) and pharmacodynamics ( PD) of 
single, 
ascending, oral doses (5, 20, 80, 320, and 1000 mg) of the prodrug ACT -281959 
were assessed in 40 healthy, male subjects (n = 6/2 on active/placebo per dose level).   
In Part II, the safety, tolerability and PK of single, oral doses of prodrug formulations I 
and II 
(70 mg) and ACT -246475 (50 mg) were determined in [ADDRESS_504562] -246475 was generally low. Accordingly, the IPA was also limited.  
[IP_ADDRESS] Study AC -076-101 
This was a randomized, double -blind, pla
cebo- controlled, single -ascending dose (SAD) 
study to investigat e the safety, tolerability, PK and PD of ACT -[ADDRESS_504563] 2017, page 27/[ADDRESS_504564] 2017 -003332 -36 
Doc No D-17.029  
 
 
 
 
 
   
 
  
[IP_ADDRESS] Study 
AC-076-[ADDRESS_504565] â€“246475 after s.c. ( Part A) and sublingual 
(s.l.; P art B) administration to healthy male subjects.  
This study has been clinically completed and the database locked. The clinical study 
report  (CSR)  is not yet 
available.  
In Part A, there were a total of  48 subjects e xposed (6 subjects rec eiving active treatment 
and 2 subjects receiving placebo per dose level).  
ACT â€“246475 has been determined to be safe and tolerated at each s.c. dose level ranging 
from 1  mg to 32 mg.  
The ov
erall AE incidence was 12.5% (6  of 48 subjects exposed) w ith no indication of 
dose dependency. There were [ADDRESS_504566] -246475 (13.9%) vs 1 of 12 after placebo (8.3%). Each AE after administration of 
ACT â€“246475 was mild and transient. 
â€¢In the 2 mg dose group, 2 subjects reported 1 AE each (headache;  dizziness) after
administration of ACT â€“246475.
â€¢In the [ADDRESS_504567] â€“246475 (rhinorrhea; head
ache; dizziness, nausea and hyperhidrosis).
â€¢One subject reported 3 AEs afte r administration  of placebo (catheter site erythema,
nausea, and headache).
â€¢In the other dose groups (1 mg, 4  mg, 16 mg, and 32 mg), no AEs we re reported.

ACT -[ADDRESS_504568] 2017, page 28/[ADDRESS_504569] 2017 -003332 -36 
Doc No D-17.029  
There were no deaths, SAEs, bleeding events , or AEs leading to discontinuation of the 
study. No clinically relevant changes in laboratory variables , vital signs, ECG variables , 
body weight, physical examination , or vigilance tests were observed. 
Peak plasma concentrations were reached within app roximately  30â€“45 min and t Â½ ranged 
from 1. 3â€“9.2 h. Exposure increased  in a dose-proportional manner. 
At each dose level, peak IPA was achieved within app roximately  15â€“[ADDRESS_504570] -dosing. 
Peak %IPA
 exceeded 85% at doses â‰¥  4 mg. The duration of PD effects was dose 
dependent. M ean %IPA â‰¥  85% was sustained for approximately  [ADDRESS_504571] â€“246475, respectively. 
In Part B, there were a total of 8 subjects exposed (6/2 on active/place bo). ACT -[ADDRESS_504572] â€“246475: lightheadedness in 
[ADDRESS_504573] -246475 has shown a favorable PK/PD and safety profile in animal 
models, confirmed in studies conducted in healthy subjects . This Phase [ADDRESS_504574] of 2 different doses and 2 different sites of injection (abdomen vs thigh) on the PD, PK, 
safety and tolerability of ACT -[ADDRESS_504575]  are related to 
an increased risk of bleeding events [ Eikelboom 2006, Wiviott 2007, Amlani  2010] .  
In nonclinical studies , ACT -[ADDRESS_504576]  lower  risk of bleeding compared 
to ticagr
elor [Section  1.3.1] . This may be related to a different mechanism of action  than 
that of ticagrelor : in contrast with ticagrelor, A CT-[ADDRESS_504577] 2017, page 29/[ADDRESS_504578] active 
internal bleed ing (exclusion criterion #3) or who are at high risk of bleeding: subject s 
with a history of recent bleeding disorder (exclusion criterion #3), subjects taking 
anticoagulants as back
ground therapy (exclusion criterion #6), and subjects with known 
platelet disorders 
(exclusion criterion  #7). 
In this study, the highest dose planned to be used is [ADDRESS_504579] commonly reported AE  
[see S ection [IP_ADDRESS]] . There were no deaths, SAEs, 
bleeding events or AEs leading to 
discontinuation. No clinically relevant changes in laboratory variables , vital signs, ECG 
variables , body 
weight, physical examination, or vigilance tests were observed. 
Accordingly, s.c. administration of ACT -[ADDRESS_504580] -246475 study enrolling patients . Accordingly, an 
independent S afety Event C ommittee  [Section 3.4] will have overall r
esponsibility for 
safeguardin g the interests of subjects by [CONTACT_400401] (with specific 
focus on bleedi
ng events occurring within 3 days of study treatment administration) and 
making appropriate recommendations based on the reported data, thus ensuring that the 
study is conducted to  the highest scientific and ethical standards.
1.5.[ADDRESS_504581] to be eligible  has been set to 40 kg (inclusion criterion #6), and subjects with 
low hemoglobin at baseline (exclusion criterion #4) or significant recent blood loss 
(exclusion criterion #
5) are exclud ed. For the subjects with a body weight between 
40 and 50 kg  (88.2 and 110 lbs), the 
assessments requiring blood collec
tion have been 
reduced: Light transmission ag gregometry ( LTA ) platelet aggregation tests (supportive 
assessment ) will not be performed in  order to minimize the blood volume collected in 
these low- weight subjects. For these subjects, the total volume of blood collected for 
study purpose s will be approximately [ADDRESS_504582] 2017, page 30/[ADDRESS_504583] 2017 -003332 -36 
Doc No D-17.029  
collected for study purpose s will not exceed a maximum of approximately 3.5% of total 
blood volume over the 3- week study period and 2.5% of total blood volume over a single 
day. This is in compliance with  the r ecommendations for maximum blood collection for 
research purposes from several Independent E thics Committee s or Institutional Review 
Boards (IECs /IRBs ), and is therefore considered to represent a minimal risk for the 
subjects.  
1.5.3 Potential risk of unblinding  
Some study activities may potentially lead to 
unintentional unblinding . Performing the 
platelet aggregation tests 
may provide information that allow s guessing of the actual 
treatment received (ACT -246475 or placebo). In order to limit the risks of unblinding, 
some study- specific roles for site personnel are defined and source documents will be 
kept separately [see Section  3.3]. 
The clinical research associates (CRAs) are consider ed unblinded [see Section 5.1.5]  as 
they will have access to platelet aggreg
ation test results . They will be in contact [CONTACT_400402]. The CRA 
will be instructed to not communicate or discuss any platelet aggregation results except 
with the platelet aggregation technician. Accordingly, the risks of pote ntial bias related to 
intera ction between the CRA and site personnel are considered negligible. 
However , inadvert ent access to potentially  unblinding data (e.g. , data gathered with 
VerifyNowÂ® or LTA assays ) may still happen. Because the primary endpoint is  an 
objective PD endpoint , this is not considered critical for the study and for the reliability 
of the results. 
1.5.[ADDRESS_504584] participat ing in this 
study. However, this study is par t of the development of a new treatment addressing an 
unmet medical need that may ultimately benefit the population  of patients at high risk of 
AMI recurrence. On top of reimbursement of their study -related expenses, s ubjects 
participating to this study will get financial compensation for their time spent in the study 
in compliance with local regulations [see Section  12.4] . 
1.5.[ADDRESS_504585] procedures, the risks for subjects participat ing in this study are considered 
minimal and medically acceptable.  
It is the investigator â€™s responsibi lity to monitor the risk -benefit ratio of study treatment 
administration, as well as the degree of distress caused by [CONTACT_400403] -[ADDRESS_504586] 2017, page 31/[ADDRESS_504587] if, on balance, he/she is 
of the opi[INVESTIGATOR_400374]â€™ s well -being. 
[ADDRESS_504588] -246475 either in the thigh or in the abdome n at 2  different doses in
subjects with stable coronary artery disease (CAD) receiving conventional background
oral antiplatelet therapy (e.g., acetylsalicylic acid , P2Y 12 receptor antagonists).
2.[ADDRESS_504589] -246475, 
are: 
â€¢To assess the PK of ACT -246475.
â€¢To assess the 
impact of the injection site location (thigh vs abdomen) on the PK and
PD of AC
T-246475.
â€¢To investigate the impact of concomitant drug use, age, sex, and other covariates on
the PK and P
D of ACT-246475.
â€¢To investigate the safety and tolerability  of ACT -246475.
[ADDRESS_504590] -246475, at 2 different dose levels, in subjects with stable
CAD receiving conventional background therapy (e.g., acetylsalicylic acid , P2Y 12
receptor 
antagonists , etc. ).
Approximately 324 adult subjects with stable CAD will be random ized into 1 of the 
8 combinations of the treatment , dose , and injection site using a 2:2:2:2:1:1:1:[ADDRESS_504591] 2017, page 32/[ADDRESS_504592] -246475 or matching placebo , either in the thigh or in the abdomen. 
Treatment group allocation will be s tratified based on  baseline platelet reactivity value  
(expressed as P2Y 12 reaction units  [PRU ]) measured on Day 1 by [CONTACT_400395]Â® assay  
before ACT -246475 injection , considering the 3 following categories : high reactivity  
(PRU > 250), medium reactivity (150 â‰¤ PRU â‰¤ 250), and low reactivity (PRU < 150). 
No interim analysis is planned for this study. 
The study will be conducted at approximately 20 s ites and in 5â€“10 countries  (recruitment 
will be competitive across sites) . The list of sites including the name [CONTACT_400437], and the address and telephone 
numbers of the trial sites will be filed in the Trial Master File (TMF).  
3.1.1 Study periods  
The study comprises  the
 following  consecutive periods: 
Screening period:  Lasts 1â€“21 days; starts  with the signature [CONTACT_400438] (ICF) and ends on Day âˆ’ 1. 
Treatment period:  Lasts 2 days : Day [ADDRESS_504593] 2017, page 33/[ADDRESS_504594] 2017 -003332 -36 
Doc No D-17.029  
Follow- up period:  Lasts 28â€“35 days (i.e., 30â€“ 37 days after single administration of 
study drug). Starts on Day 3 and ends with the safety follow -up tele phone call . 
The visit schedule and protocol -mandated procedures will be performed according  to the 
table of assessments [Table 2 and Table 3] and are described in Section  7. 
The overall study design is depi[INVESTIGATOR_400375] 2. 
Figure [ADDRESS_504595] of recruitme n
t (i.e., first ICF  signed  for the first subject ) 
and ends with the last visit of
 the last subject.  
The overall  duration of participation in the study  (including sc reening and follow -up 
periods) for a subject will be up to [ADDRESS_504596] 2017, page 34/[ADDRESS_504597] 2017 -003332 -36 
Doc No D-17.029  
The use of 2 doses ( i.e., 8 and 16 mg ) will allow assess ment of  the dose/PK  and dose/PD  
relationship in this patient population, which will  enrich  the results already obtain ed in a 
healthy subject population [ see Section  5.1.1 for detailed rationale on dose selection ]. 
The stratification by [CONTACT_400404] P2Y [ADDRESS_504598] been selected to mimic the 
expected baseline level of P2Y 12 receptor inhibition depending on the type of background 
antiplatelet therapy  [Gurbel 2009] : PRU < 150; 150 â‰¤ PRU â‰¤ 250; PRU > 250. 
The primary PD analysis will be performed with the VerifyNowÂ® method. Results from 
the VerifyNowÂ® method are well correlated with those obtained with the LTA method 
[Varenhorst 2009, Gremmet  2015] . The VerifyNowÂ® method has been preferred as it is 
more  standardized than the LTA method; and therefore, less subject to variability in a 
multicenter study. In addition, the volume of blood required per sample is higher for LTA 
(6 mL) th an for the VerifyNowÂ® method ( 3 mL). Using the VerifyNowÂ® method will 
allow assessment of  more time points and , therefore, better characterization of the PD 
profile while requiring  less blood withdraw n from the subjects. As LTA remains a 
reference method and to allow comparison with other trials, some LTA assessments will 
be performed at selected time points [Table 3]. 
The use of a double -blind placebo- controlled design is proposed to assess the safety of 
ACT -246475 co
mpared with placebo  and will support additional exploratory analyses . 
The double -blind design applies to the treatment allocation (i.e., ACT -246475 
vs placebo). The knowledge of the dose (8 or 16 mg) and injection site is not expected to 
affect the primary objective (which is based on objective PD assessment ) or the safety 
evaluation as the study is placebo -controlled. However, to reduce the risks of bia s in 
safety reporting , the dose will be blinded to the subjects (single blind). T he injection site 
will not be blinded in this study. 
3.3 Site personnel and roles  
3.3.1 Platelet aggregation technician 
The technician (s) performing the platelet aggregation tests (VerifyNowÂ® and LTA) will 
be considered unblinded to the treatment. They must not be involved in safety 
assessment s and must not communicate with the results from the platelet aggregation 
tests to other study staff  (only the stratification group will be communicated to the person 
in charge of randomization). 
To maintain the blind, the results of the platelet aggregation tests will be entered in the 
case report form ( CRF ) only by [CONTACT_400405]. Up to unblinding of the study, the source documents for platelet aggregation 
assays will be kept in a separate location from the subjects â€™ other source document s and 
will only be  accessible to the platelet aggregation technician(s)  and to the CRA. 
ACT -[ADDRESS_504599] 2017, page 35/[ADDRESS_504600] population description 
This study will enroll adult male and female subjects aged 18 â€“85 years  (inclusive) with 
stable  CAD, as defined by  a history of CAD with coronary artery stenosis â‰¥ 50% on 
coronary angiogram or previously documented MI occurring more than  3 months before 
randomization. 
Subjects with significant medical conditions (e.g., active internal bleeding, history of 
recent bleeding disorder, platelet disorders, subjects requiring
 dialysis ) as well as subject s 
taking oral anticoagulants as background treatment are not eligible to enter the study.  
Eligible subjects must be able and willing to give informed consent for participation in the clinical study.  
4.[ADDRESS_504601] the general population of patients with  
CAD. 
Among these patients, those with prior MI are at high er risk of recurrent ischemic events 
[Fox 2008 ]. Such pat
ients are treat ed with acetylsalicylic acid  as life -long background 
therapy. In addition, t he Ame
rican College of Cardiology/American Heart Association 
and ESC guidelines for the management of patients with STEMI and non-STEMI 
recommend DAPT for the secondary prevention of recurrent ischemic events for up to 
1 year after the acute coronary syndrome ( ACS ) event , a duration that may  be shortened 
or extended in s elected patients if required [Steg 2012; Oâ€™Gara 2013; Amsterdam  2014; 
Roffi  2016; Levine 2016 ]. The target population for this study will in
clude patients with 
coronary artery stenosis and patients who ha ve experienced an  AMI more than [ADDRESS_504602] 2017, page 36/[ADDRESS_504603]. 
Ticagrelor and prasugrel are both expected to already provide more  than 80% of IPA in 
patients who are compliant with their treatment [PrasugrelÂ® SmPC , TicagrelorÂ® SmPC ]. 
It cannot be excluded that, despi[INVESTIGATOR_2391] w
ith a potent oral P2Y [ADDRESS_504604]:  
1. Signed  informed conse nt prior to any study-mand ated procedure.
2. Male and female subjects aged from 18â€“85 years , inclusive.
3. For women of childbeari
ng potential: Negative  urine pregnancy test at Visit  1 and
at Visit 2 before randomization.
4. Stable CAD defined by [CONTACT_400406] y of the following conditions:
a.History of 
CAD with coronary artery stenosis on coronar y angiogram â‰¥ 50%.
b. Previously documented MI occurring more than [ADDRESS_504605] 1 month prior to
ra
ndomization.
6. Body weight â‰¥ 40.0 kg (88.2 lbs).
4.[ADDRESS_504606]:  
Conditions associated with atherosclerosis: 
1.ACS, PCI or any intervention for peripheral artery disease within  3 months prior to
randomiz ation .
2.Acute ischemi
c stroke or transient ischemic attack ( TIA) within 3 months prior to
randomization.
M
itigation of bleeding risks:  
3.Active internal bleeding, or medical history of recent (< 1 month) bleeding disorders
or conditions associated with high r
isk of bleeding (e.g., clotting disturbances,
gastrointestinal bleed, hemoptysis).
ACT -[ADDRESS_504607] 2017, page 37/[ADDRESS_504608] 2017 -003332 -36 
Doc No D-17.029  
4. Hemoglobin â‰¤ 10 g/dL at screeninga.
5.Loss of at leas t 250 mL of blood within 3 months of screening.
6.Use of  anticoagulants ( oral, p arenteral)  or fibrinoly tic therapy  within 24 h prior to
screening  (Visit 1).
7.Known platelet disorders (e.g., thrombasthenia, thrombocytopenia, von Will ebrand
disease).
Conditions  that may prevent subje ct from complying with study requirements or 
may be a confounder for the study interpretation:  
8.Pregnant or breast feeding women.
9. Uncontroll
ed hypertension according to investigatorâ€™s judgment.
10. Known and documented modera t
e or severe hepatic impairment.
11.End-stage renal failure requiring dialysis.
12.Any clinicall
y significant findings on a physical exam, or laboratory tests prior to
screening that in 
the investigator â€™s judgment would preclude safe or reliable
participation of a subject in  the study.
13.Concomitant disease s (e.g., advanced liver  cirrhosis, mental illness,
neurodegenerative disease, terminal malignancy , etc.) or conditions (e.g., inability to
communicate well with the investigator in the local language ) that, in the opi[INVESTIGATOR_277392] , may prevent subject from  comply ing with study requirements  or may
be a confounder for the study interpretation.
14.Veins unsuitable for i.v. puncture on either arm (e.g., difficult to locate, access, or
puncture) according t
o the investigatorâ€™s judgment.
15.Clinically relevant skin disease that prevents s.c. injection  in the thigh  or abdomen,
a
ccording to the investigatorâ€™ s judgment.
16.Use of inhibitors of organic anion-transportin g polypeptide ( OATP )1B1 or  OATP1B3
at screening (Visit 1).
17. Known hypersensitivity to  ACT -246475, any of its excipi[INVESTIGATOR_840] , or drugs of the P2Y [ADDRESS_504609] 2017, page 38/[ADDRESS_504610] 1 of the 
following criteria:  
â€¢Previo
us bilateral salpi[INVESTIGATOR_1656], bilateral salpi[INVESTIGATOR_8936] -oophorectomy or hysterectomy ,
â€¢Postmenopausal (defined as 12 consecutive months with no menses without an
alternative medical cause [ Inte
rnational council for harmonization (ICH)  M3
definition]),
â€¢Premature ovarian failure (confirmed by a specialist), XY genotype, Tu rner
syndrome, uterine agenesis
.
The reason for not being of childbearing potential w ill be recorded in the CRF.  
4.5.2
 Acceptable methods of contraception  
Women of childbearing potenti
al [see definition in Section 4.5.1]  must use one of th e 
following methods of birth cont
rol from Screening up to at least 30 days after study 
treatment administration : 
1. Diaphragm / female condom / cervical cap  / partnerâ€™s use of a condom.
2.Intra -
uterine devices.
3.Oral or injectable c
ontraceptive agents, implants, or transdermal contraceptiv e
hormone patches. If a hormonal contraceptive is chosen, it must be taken for at least
1 month prior to randomization.
4.Sterilization method (tubal ligation / occlusion, or partner â€™s vasectomy).
5.True abstinen
ce from intercourse with a male partner only when this is in line with
the preferred lifestyle of
 the subject.
Rhythm methods are not considered as acceptable methods of contraception for this study.  
The methods of birth cont
rol used (including non- pharmacological methods) mu st be 
recorded in the CRF.  
5 TREATMENTS 
5.1 Study treatment  
5.1.1 Investigational treatment and matching placebo : Description and rationale  
Study treatment  for s.c. administration will b e available as sealed glass vials in 1 strength: 
[ADDRESS_504611] -246475A (hydrochloride salt of 
ACT -[ADDRESS_504612] 2017, page 39/[ADDRESS_504613] -246475) or matching placebo to be reconstituted with 1 mL of water for injection. 
The s.c. formulation contains mannitol as an inactive ingredient.  
Study treatment will be given as a single dose , ad ministered s.c. at site by [CONTACT_134323] (e.g., nurse, physician). 
ACT -246475 at 2 different doses (8 and 16 mg) and placebo will be administered  during 
this study. The ACT -[ADDRESS_504614] been selected based on data from the SAD 
AC-076-102 study and on modeling to meet the following criteria:  
â€¢The low dose (8 mg) is the minimal dose achieving at least 85% IPA for 3 h which
corresponds to a time period during which complete suppression of platelet reactivity
is needed before specific in -hospi[INVESTIGATOR_400376]  [Montalescot  2014].
â€¢The high dose ( 16 mg ) provides IPA of at least 85%  in no more than 5% of the
subjects at 8  h. This corresponds to the maximal time accepted to limit interference
with invasive and/or pharmacological standard of care of AMI .
These [ADDRESS_504615] enough to al low further modeling  of the optimal 
phase 3 dose based on study data.  
Note: onset of action of ACT-246475 is not dose-dependent and therefore did not account 
for dose selection. 
5.1.2 Study treatm
ent supply  
Manufacture, labeling, pa
ckaging, and supply of study treatment will be  conducte d 
according to Good Manufacturing Practice, Good Clinic al Practice (GCP), and any local 
or national regulatory requirements. 
All study treatment supplies are to be used only in accordance with this protocol, and not 
for any other purpose. 
[IP_ADDRESS] Study tr
eatment packaging and labeling 
Study treatment ( ACT -246475 and m atch
ing placebo ) will be provided in sealed glass 
vials as a lyophiliz ate to be reconstituted by a pharmacist or an authorized person as per 
local regulation.  
Study treatment will be labeled to comply with the applicable laws and regulations of the 
countri es in which the study
 sites are located.  
[IP_ADDRESS] Study treatment distribution and storage 
The investigator is respons
ible for safe and proper handling and storage of the study 
treatment at the investigationa
l site and for ensuring that the study treatment is 
administered only to subjects enrolled in the study and in accordance with the protocol. 
ACT -[ADDRESS_504616] 2017, page 40/[ADDRESS_504617] 2017 -003332 -36 
Doc No D-17.029  
[IP_ADDRESS].1 Study treatment distribution 
The study centers will be supplied with study treatment according to the centers â€™ needs, 
depending on the r
ate of subject enrollment. Each  center will have an individual stock of 
study treatment, which will be re -supplied continuously as soon as a predefined minimum 
number of study treatments have been reached.  
[IP_ADDRESS].[ADDRESS_504618] 
on a weekly basis at the site. The sponsor /delegate will provide a temperature log; 
however, the use of the log is not mandatory if the site has an acceptable means of 
recording the temperature. Any temperature recording system routinely used at the site will be acceptable as long as all required information is included and cer tification of 
calibration is provided. If the temperature is captured electronically, a print -out will be 
made available to the CRA during each on -site visit.  
If a deviation from the approved temperature range is identified by [CONTACT_5243], the 
deviati on must be repor 
ted to the CRA, preferably in writing and with supporting 
documentation (e.g., copy of the temperature log showing data for all excursion days). The CRA will immediately contact [CONTACT_400407]. The affected study 
treatment must not be used (e.g., it will be segregated physically at the study center) until confirmation from the sponsor is obtained that its use is safe. If the temperature deviation 
is outside of the acceptable limit, the study treatment will be kept segregated at the study 
center and returned to the sponsor following internal study treatment return processes. 
New study treatment supplies will be provided to the study center.  
Temperature deviations correspondence must be kept in the Investigator S ite File (ISF). 
[IP_ADDRESS] Study trea 
tment return and destruction  
On an ongoing basis
 and/or on termination of the study, the CRA will collect used and 
unused treatment kits, 
which will be returned to the warehouse. In certain circumstances, 
used and unused study treatment container s may be destroyed at the site once study 
treatment accountability is finalized , has been verified and reconciled by [CONTACT_400408], and written permission for destruction has been obtained from the sponsor. Further details are provided in the study treatment handling manual.  

ACT -[ADDRESS_504619] 2017, page 41/[ADDRESS_504620] 2017 -003332 -36 
Doc No D-17.029  
5.1.3 Study treatment assignment and dispensing  
[IP_ADDRESS] Study t reatment assignment  
At Visit 2, after
 having verified that the subject meets all inclusion criteria and none of 
the exclusion criteria, and after 
performing the pre -dose VerifyNowÂ® assessments, the 
platelet aggregation technician will provide the PRU stratification group to the person 
who will randomize the subject using the Interactive Response Technology ( IRT) system. 
The IRT will assign a randomization number to the su bject and will assign the treatment 
kit number as well as the dose  and injection site , which matches the treatment arm 
assigned by [CONTACT_400409]. 
The randomization list will be generated by [CONTACT_400410] (CRO). 
[IP_ADDRESS] Study t reatment
 dispensing  
The IRT will a
llocate one treatment kit (1 vial) per subject at randomization. In the event 
of deviation from study treatmen
t preparation instructions [ Section  5.1.4 ] (e.g. , breach of 
sterility conditions, incorrect 
dose), a new kit will be requested via the dispensing module 
of the IRT and preparation steps will be started again. The protocol -mandated study  
treatment dispensing procedures may not be altered without prior written approval from 
the sponsor. An accurate record of the date and amount of study treatment dispensed to 
each subject must be available for inspection at any time.  
5.1.[ADDRESS_504621] or an authorized person accor
ding to local regulation. 
The sealed glass vials containing the study treatment  will be reconstituted with 1 mL of 
wat
er for injection. The resulting stock solutions will be at a concentration of 20 mg/mL 
ACT -246475. For subjects randomized to receive the [ADDRESS_504622] -246475 or its 
matching placebo, dilution of the stock solution will be performed with 1 mL of NaCl 
0.9% to obtain the required concentration for injection [Table 1]. For all doses , the total 
volume administered will be 0.8 mL (
i.e., concentration of the solutions adapted). 
The reconstituted ACT -[ADDRESS_504623] 2017, page 42/[ADDRESS_504624] be available for inspection 
at any time.  
  
In Table 1
, the preparation of doses of the study treatment is described; detailed 
instructions are given in the st
udy treatment  handling manual. 
The date and start time of preparation of the injection solution as well as the procedure must be recorded on source documents. 
T
able 1 Preparation of study treatment  for subcutaneous  administration 
Study 
treatment  Dose  Volume of 
water for 
injection  Volume of 
NaCl 0.9%  Stock solution 
concentration  Aliquot of stock 
solution  to be 
administered  
ACT -246475 
or placebo  8 mg  1 mL  1 mL  10 mg/mL  0.[ADDRESS_504625] -246475 
or placebo  16 mg 1 mL  - 20 mg/mL 0.[ADDRESS_504626] of the study will 
remain blinded to the study treatment (ACT -246475 or placebo). 
The dose (8 mg or 16 mg) will be blinded only for the subject. The inject ion site (thigh or 
abdomen) will not
 be blinded. 
Sponsor staff responsible for clinical trial supply distribution will be partially unblinded 
at depot level  to ensure 
adequate study oversight , but will remain blinded to subject 
randomization and subject tr eatment.  
Sponsor staff responsible for suspected unexpected serious adverse reaction (S[LOCATION_003]R) 
management may be unblinde
d to some subject treatment allocations. These persons will 
be clearly identified, their unblinding will be documented in the TMF  and they will not 
take part in any Clinical Trial Team (CTT) meetings after study set- up has been 
completed.  

ACT -[ADDRESS_504627] 2017, page 43/[ADDRESS_504628] results (VerifyNowÂ® and LTA) and will , therefore , 
be considered unblinded (they will not have access to the randomization list). 
The randomization list will be  kept strictly conf idential and accessible only to authorized 
persons, sponsor quality assurance (QA), and the PK analytical laboratory who are not 
involved in the conduct of the study, as long as the blinding needs  to be maintained until 
final data analysis . 
The investigational treatment and its matching placebo are indistinguishable, and all 
treatment kits will be p
ackaged in the same way.  
5.1.6 Unblinding  
[IP_ADDRESS] Unblinding for final
 analyses 
Full randomization in
formation will be made available for data analysis only after 
database closure, in 
accordance with  the sponsor quality system (QS) documents. 
[IP_ADDRESS] Unblinding for interim analyses 
Not applicable.  
[IP_ADDRESS] Unb
linding for suspected unexpected serious adverse reactions  
If a S[LOCATION_003]R occur
s for a subject participating in the study, the sponsorâ€™s Global Drug 
Saf
ety department  or a representative will request the unblinding of the treatment 
assignment. The treatment assignment will not be communicated to site personnel or to the sponsor CTT. Unblinded S[LOCATION_003]R information will be provided to respective HA and 
IECs or  IRBs only. S[LOCATION_003]Rs will be reported to investigators in a blinded fashion. 
[IP_ADDRESS] Emergency procedure for unblinding  
The investigator, s
tudy personnel , and sponsor personnel must  remain blinded to the 
subject â€™s treatment assignment. The identity of the study treatment may be revealed only 
if the subject experiences a medical event, the management of which would require 
knowledge of the blinded treatment assignment. In this case, the investigator will receive 
the unblinded treatment assignment through the IRT. In these situations, the decision to unblind will reside solely with the investigator. Whenever it is possible, and if it does not 
interfere with (or does not delay) any decision in the best interest of the subject, the investigator will be  invited to discuss the intended unblinding with spons or personnel. 
The occurrence of any unblinding during the study must be clearly justified and explained by [CONTACT_272250]. In all cases, sponsor personnel must be informed as soon as 
possible before or after the unblinding. 
The circumstances leading to u nblinding must be documented i n the ISF and CRF. 
ACT -[ADDRESS_504629] 2017, page 44/[ADDRESS_504630] 2017 -003332 -36 
Doc No D-17.029  
5.1.7 Study treatment accountability and compliance with study treatment  
[IP_ADDRESS] Study treatment accountability  
The inventory of st
udy treatment dispensed and returned (i.e., study -treatment 
accountability
) must be performed by [CONTACT_8786]. It is to be recorded by [CONTACT_400411] -treatment dispensing and accountability log and in the CRF, verified and 
reconciled by [CONTACT_400412]. The study 
treatment accoun tability in the CRF will include at least the following information for 
each study treatment unit (i.e ., vial ) dispensed to the subject: 
â€¢Dispensed vial  number
â€¢Date vial dispensed
A
ll study treatment s
upplies, including partially used or empty vials , must be retained at 
th
e site for review and reconciliation by [CONTACT_2689].  
[IP_ADDRESS] Study treatment compliance  
Study treatment co
mpliance is based on administration of the study treatment as allocated 
b
y IRT. Any deviation from  the randomization allocation will be reported as a protocol 
deviation. 
5.1.8 Study treatment dose adjustments and interruptions  
Study treatment do
se adjustments are not permitted . 
Study treatment interruptions are not applicable for this single -dose study. 
5.1.9 Prematur
e discontinuation of study treatment  
Not applicable (single -dos
e study). 
5.1.10
 Study -specific criteria for in terruption / premature discontinuation of study 
treatment  
Not applicable (single -dose study). 
5.[ADDRESS_504631] 2017, page 45/[ADDRESS_504632] 2017 -003332 -36 
Doc No D-17.029  
A therapy that is study treatment concomitant is any treatment that is either ongoing at 
the start of study treatment or is initiated up to 48 hours after study treatment 
administration . 
5.2.2 Reporting of previous/concomitant therapy in the case report form  
The use of all st
udy concomitant therapy  (including contraceptives and traditional and 
alternative medicines, e.g., plant -, animal -, or mineral -based medicines) will be recorded 
in the CRF. 
Previous therapi[INVESTIGATOR_400377] â€™s underlying CA D will be recorded in the CRF if 
discontinued less than 1 month (â‰¤ 30 days) prior to signing of the informed consent. The generic name, start/end dates of administration (as well as whether it was ongoing at 
start of treatment 
and/or End-of-Study [ EOS ]), route, dose, and indication will be 
recorded in the CRF.  
5.2.[ADDRESS_504633] treatment (s) (including 
oral P2Y 12 receptor antagonists  and acetylsalicylic acid ) as prescribed  (treatments and 
doses), from Visit 1 (screening) and up to the last PK  or PD  blood sample collection 
(whichever is  latest) . 
5.2.[ADDRESS_504634] PK or PD  blood 
collection (whi chever is latest) : 
â€¢Fibrinolytic therapy  (e.g., streptok inase, alteplase, etc. )
â€¢Anticoagulants (e.g., Coumadin, warfarin, anti Xa inhibitors, dabigatran, heparin)
â€¢OATP1B1 and OATP1
B3 inhibitors (e.g., cyclosporine, eltrombopag, lapatinib,
lopi[INVESTIGATOR_054], rifampi n, ritona
vir)
Initiation of any of the following medications is prohibited from screening  up t o last PK 
or PD blood collection (whichever is  latest):  
â€¢Oral P2Y 12 receptor antagonists (e.g., clopi[INVESTIGATOR_7745], prasugrel, ticagrelor)
â€¢Cangrelor
[ADDRESS_504635] 2017, page 46/[ADDRESS_504636] as a 
PRU  < [ADDRESS_504637] 3  h, as measured via the 
VerifyNowÂ® assay . This corresponds to inhibition of ADP -induced platelet aggregation 
(IPA) > 80% [Gaglia  2011, Gremmel  2009, Varenhorst  2009] . 
6.2.[ADDRESS_504638]
asma concentration -time profiles. PK endpoints include: 
â€¢Cmax.
â€¢tmax.
â€¢The AUC from ti me zero to 24 h time point (AUC 0â€“24h).
6.3 Safety endpoints 
The safety endpoints will be assessed up to EOS : 
â€¢Treatment -emergent AEsb (TEAEs)  and SAEs.
â€¢All AE s and SAEs.
â€¢Change in vital signs (systolic and diastolic a
rterial BP and pulse rate) from baseline
to all assessed time
 points during the study.
â€¢Treatment -emergent ECG abnormalities .
â€¢Change from baseline 
to each measured time point in ECG variables: heart rate, and
the intervals: PQ/PR , QRS, QT, RR, QT corrected with 
Bazet tâ€™s formula ( QTcB ), QT
corrected with Fridericiaâ€™ s formula (QTcF ).
â€¢Change from baseline to each measured time point for clinical laboratory tests.
â€¢Treatment -emergent marked laboratory abnormalit
ies.
[ADDRESS_504639] be per
formed 30â€“37 days after the single 
administration  of study treatment.  
b A treatment -emergent AE is any AE temporally associated with the administration  of study treatment ( until 48 h after 
study treatment administration ) whether or not considered by [CONTACT_86190].  
ACT -[ADDRESS_504640] 2017, page 47/[ADDRESS_504641] 2017 -003332 -36 
Doc No D-17.029  
7.1.1 Screening/re- screening  
Screening starts with the signature [CONTACT_28513]. The date on which the first 
screening assess
ment is performed corresponds to the date of the Screening visit. 
It is the responsibility of the investigator/delegate to obtain written informed consent 
from each subject p
articipating in this study after adequate face -to-face explanation of the 
objectives, methods  and potential hazards of the study. The subjects who agree to 
participate in the study and the investigator/delegate must sign the ICF prior to any study- related assessment or procedure.  
Subjects who have signed informed consent when the enrollment target has been met may still be randomize
d. 
It is permitted to re -screen subjects once , if the reason for non- eligibility was transient 
(e.g., abnormal laboratory test, insufficient wa shout period of a forbidden medication). 
All screening assessments must be repeated at the time of re- screening  unless they were 
performed within 1 week (7 days) of re- screening . 
Screening (and re- screening) will be  performed through the IRT system which will 
provide a unique subject number. 
7.1.2 Unscheduled visits  
Unscheduled visits m
ay be performed at any time during the study. Depending on the 
reason for the unsch
eduled visit (e.g., AE), appropriate assessments will be performed 
based on the judgment of the investigator and the results will be recorded in the CRF. 
After an unscheduled visit, the regular scheduled study visits must continue  according to 
the planned visit and assessment schedule. 
ACT -[ADDRESS_504642] 2017, pa ge 48/[ADDRESS_504643] 2017- 003332- 36 
Doc No D-17.029  
Table 2 Visit and assessment schedule  
PERIOD  SCREENING P ERIOD  TREATMENT PERIOD  FOLLOW-UP PERIOD  
Visit  Visit 1  Visit 2 
(Randomizationc) Visit 3  EOS Visit (Visit 4;  
Teleph one call)  
Study Day  Day âˆ’21 to Day âˆ’1 Day 1 Day 2 Study treatment  administration + 
30â€“37 days  
Informed consent  X 
Eligibility  X Xf 
Demogra
phics and m edical history  X 
Physica
l examination  X Xa X 
Body wei
ght and height  X 
Previo
us/concomitant therapy  X X X X 
Urine pregnancy testg X X X 
Vital sig
ns (BP,  Pulse rate) X Xb Xb 
12-lead E
CG Xb Xb 
Laborato
ry testseX Xa, f Xh 
PK b lood s
ampling Xb Xb 
VerifyNowÂ®X Xb, c Xb 
LTA  (for patients â‰¥ 50.0 kg only) dX Xb, c 
s.c. in
jection  (ACT-246475 or placebo) X 
AEs/SAEs X
 X X X 
a. Physical examination and laboratory tests do not need to be repeated if screening assessments were performed within 7 days of  Visit 2  and are to be performed pre -
dose.
b. Refer to  Table 3 for detailed timing of assessment s.
c. Randomization will be performed after the pre -dose blood sampling for Verify NowÂ® and LTA assessments on Day 1.  The dose allocated (8 mg or 16 mg) must not
be communicated to the subject.
d. No blood sam ples are to be collected for LTA assays for subjects with body weight < 50.0 kg (110 lbs), only VerifyNowÂ® assays are performed for these subjects.
ACT -[ADDRESS_504644] 2017, pa ge 49/[ADDRESS_504645] results are available.
AE, Adverse event ; BP, Blood pressure ; ECG, Electrocardiogram ; EOS , End-of-Study; INR, International normalized ratio; LTA , Light transmission aggregometry ; 
PK, Pharmacokinetics ; s.c., Subcutaneous ; SAE , Serious adverse event . 
Table 3 Time points of main study  assessments  
PERIOD  TREATMENT PERIOD  
Visit  Visit 2 (Randomizationa) Visit 3  
Study Day  Day 1b Day 2b 
Time point  Pre-dose  0 min 15 min 
Â±1 min 30 min 
Â±2 min 1h 
Â±3 min 2h 
Â±6 min 4h 
Â±12 min 8h 
Â±24 min 24h 
Â±2h 
Vital signs (BP , Pulse rate) X X X X X X X  
12-lead ECG X Xd X 
PK Bl
ood sampling X X X X X X X
 X 
VerifyNowÂ®Xa X X X X X X  X 
LTA (for patients â‰¥ 50.0 kg only)cXa X X X X 
s.c. in
jection  (ACT-246475 or placebo) X 
a. Randomization will be performed after pre -dose blood sampling for Verify NowÂ® and LTA assessments on Day 1.  The dose allocated (8 mg or 16 mg) must not be
communicated to the subject.
b. The following order of assessments is to be followed (as applicable): PK sample (to be collected at the protocol -defined time point), VerifyNowÂ® sample, LTA
sample.
c. No blood sam ples are to be collected  for LTA assays for subjects with body weight < 50.0 kg (110 lbs), only VerifyNowÂ® assays are performed for these subjects.
d.Time window for performing the post -dose ECG is Â±30 min.
BP, Blood pressure ; ECG, Electrocardiogram ; EOS , End-of-Study; LTA , Light transmission aggr egometry ; PK, Pharmacokinetics ; s.c., Subcutaneous .
ACT -[ADDRESS_504646] 2017, pa ge 50/[ADDRESS_504647] 2017 -003332 -36 
Doc No D-17.029  
7.2 Study assessments 
The study assessments and their respective timing  are listed in  Table 2 and Table 3. 
All study assessments will be  performed by [CONTACT_400413] : medica l, nursing, 
or specialist technical personnel , and will be  recorded in the CRF, unless otherwise 
specified . Study assessments performed during unscheduled visits will also be recorded 
in the CRF. It is recommended to perform physical examination and measure vital signs 
(BP and pulse rate) prior to the blood samplings. 
At the PK/PD time points, the following order for blood sampling is to be applied : 
1. H ematology and chemistry samples (if 
any).
2.PK sample (to be collected at the protoc
ol-defined ti me point according to the time
window defined in Table 3).
3.VerifyNowÂ® sample .
4.LTA sample .
Calibration certificates  / evidence of equipm
ent maintenance  for the below- lis ted 
equipment used to perform study assessments must be available prior to screening of the first subject . Calibration certificates of other equipment must be availa ble as per local 
requirements : 
â€¢Temperature measurement devices for study treatment storage area and freezer  used
for PK samples storage .
â€¢VerifyNow
Â® and LTA devices.
â€¢Centrifuges used for preparation of the platelet s for LTA assay.
7.2.1 Demographics / baseli
ne characteristics  
Demographic and baseline characteristic data to be collected on all subject s, including 
age, sex, race, and ethnicity. Relev
ant medical history  / current medical conditions (e.g., 
chronic and ongoing acute conditions, serious past conditions) present before signing informed consent will be recorded on the medical history CRF form . Where possible, 
diagnoses and not symptoms will be recorded. 
Medical history of special interest will be captured on the specific Medical History CRF 
form and includes, when applicable, the date of th 
e most recent event for : 
â€¢MI, stroke, and TIA .
â€¢PCI or coronary artery  by[CONTACT_9292] .
â€¢P
eripheral vascular surg
ery.
ACT -[ADDRESS_504648] 2017, pa ge 51/[ADDRESS_504649] the following data will be recorded in the CRF 
if available:  
â€¢Baseline demographics and physical characteristics (i.e., age, race/ethnicity, body
weight, height, sex).
â€¢LTA  and VerifyNowÂ® assessment results .
â€¢Central laboratory and central ECG results.
â€¢Reason for scr
eening failure.
â€¢AEs and SAEs.
7.2.2 Efficacy assessments  
Not ap
plicabl
e. 
7.2.3 Pharmacokinetic and pharmaco
dynamic assessments  
[IP_ADDRESS] Pharmacodynamic assessments 
[IP_ADDRESS].[ADDRESS_504650] venipuncture or via an i.v. catheter placed in 
an antecubital or large forearm vein in the 
arm, using 18 â€“21 gauge needles.  
Blood will be drawn into 3- mL vacuum tubes: 2 samples for LTA assay  and one sample 
for VerifyNowÂ® assay. Collection tubes for both LTA and VerifyNowÂ® assays will 
contain phenylalanine -proline-arginine-chloromethyl ketone (PPACK)  as an 
anticoagulant. The centrifugation step should be performed within [ADDRESS_504651] actual clock time of collection of each blood sample (including the unscheduled ones, if any) will be entered in the CRF. 
Detailed handling instructions for PD samples (LTA and VerifyNow
Â® samples) are 
provided in the laboratory manual. [IP_ADDRESS].2 Bioanalysis 
ADP -induced platelet aggregation will be evaluated by 2 diffe rent assays, VerifyNow
Â® 
and LTA, both measuring platelet -induced aggregation as an increase in light 
transmittance [Michelson  2009].  
ACT -[ADDRESS_504652] 2017, pa ge 52/[ADDRESS_504653] 2017 -003332 -36 
Doc No D-17.029  
All PD measurements will be performed at the site by [CONTACT_400414]. Detailed instructions for the analysis of the PD samples (LTA and 
VerifyNowÂ®) are provided in the laboratory manual. 
[IP_ADDRESS].2.1 VerifyNowÂ® Assay  
The blood sample will be inserted into the calibrated VerifyNowÂ® system. 
Platelet -induced aggregation is measured with ADP as the agonist. The assay will be run 
according to the manufacturer â€™s instructions. The VerifyNowÂ® system will provide the 
results as PRU, corresponding to the extent of ADP -mediated aggregation measured in 
the ADP channel.  
The VerifyNowÂ® system will be used with 2 different tests depending on local 
availability:  
â€¢The VerifyNowÂ® P2Y12 test reports  platelet aggregation as PRU. In addition, a
second channel with an internal standard consisting of thrombin receptor agonists isused for calculation of the percent of platelet aggregation inhibition. The VerifyNow
Â®
P2Y12 test
 is only available in Europe.
â€¢The VerifyNowÂ® PRU test does not have  an internal standard and only repor ts
platelet aggregation as PRU. It is globally available and will be used where theVerifyNow
Â® P2Y12 test is not available.
[IP_ADDRESS].2.2 Light transmission p latelet aggregometry  
The two 3 mL LTA blood samples w ill be centrifuged at 200 g for 7 min, the rotor should 
then come to a halt without brakes (brakes position 0 = switched off). This will allow for 
preparation of PRP. The assay will be performed with a light transmission aggregometer approved by [CONTACT_456] (e.g., Chrono- log 490, PAP -4, PAP -8, APACT), recording the 
aggregation after addition of [ADDRESS_504654] for 6 min. The results are expressed as a percent change in light transmittance at maximum peak platelet aggregation and at 
final platelet aggregation after 6 min, calculated relative to the baseline sig nal of 0%. 
The measurements will be performed in duplicate.  
[IP_ADDRESS] Pharmacokinetic assessments  
[IP_ADDRESS].[ADDRESS_504655] venipuncture or via an i.v. catheter placed in an 
antecubital vein in 
the arm in a 4 mL MonovetteÂ® or eq uivalent tubes containing 
ethylenediaminetetr aacetic acid  (EDTA) .  
PK blood samples have to be processed within [ADDRESS_504656] 2017, pa ge 53/[ADDRESS_504657] actual clock time of collection of each blood sample will be entered in 
the CRF.  
[IP_ADDRESS].[ADDRESS_504658] -246475 i
n plasma will b
e performed using a va lidated liquid 
chromatography coupled to tandem mass spectrometry assay.  
The foreseen lower limit of quantification is 1  ng/mL. Concentrations will be calculated 
by [CONTACT_400415] a calibration curve. Quality control samples will be analyzed 
throughout the study. Their measured concentrations will be used to determine between -run and overall precision and accuracy of the analysis. 
7.2.4 Safety assessments  
The definitions, reporting , and follow -up of AEs, S
AEs, and pregnancies  are described  in 
Section  9. 
[IP_ADDRESS] Physical examination  
Physical examination will be performed accord
ing to site standard medical practice for 
subjects with stable CAD. 
Other exams will be performed if indicated , based on medical history and/or symptoms. 
In
formation for all physical examinations must be included in the source documentati on 
at the study site.  The observations will not be directly r
eported in the CRF. Clinically 
relevant findings that are present prior to signing of informed consent must be recorded on the Medical History CRF form . Physical examination findings made after s igning of 
informed consent  that meet the definition of an AE [Section  9.1.1]  must be recorded on 
the AE form of the CRF. 
[IP_ADDRESS] Vital signs  
Systolic and
 diastolic BP and pulse rate will be measu
red in subjects in supi [INVESTIGATOR_400378] [ADDRESS_504659] . 
[IP_ADDRESS] Weight and h eight  
Height  and body weight will be measured i
n indoor clothing but without shoes. 
[IP_ADDRESS] E
CG assessment  
A standard 12- lead ECG will be  performed with subje
ct in the supi[INVESTIGATOR_2547], a fter a 
recommended  5-minute resting time.  
ACT -[ADDRESS_504660] 2017, pa ge 54/[ADDRESS_504661] be 
reported as an AE as appropriate [see Section  9.1.1] . 
A central ECG service (see ECG manual for contact [CONTACT_8972])  will be used for ECG 
evaluation. 
Details about colle
ction of ECG data, and the reporting of results and abnormalities, can 
be found in the ECG manual provided to the investigator. 
7.2.5 L
aboratory assessments 
[IP_ADDRESS] Type of laboratory 
A central laboratory (see 
central laborato
ry manual for contact [CONTACT_8972]) will be used for all 
protocol- mandated laboratory tests, including r
e-tests due to laboratory abnormalities and 
laboratory tests performed at unscheduled visits.  
Exceptional circumstances that may require recording of local laboratory result s of the 
variables  described in Section [IP_ADDRESS] (with corresponding normal ranges) include 
hospi[INVESTIGATOR_42860] a m
edical emergency , and missing central laboratory 
results from a scheduled or unscheduled visit. If the [ADDRESS_504662] results are available.  
Central laboratory reports will be sent to the investigator. In the event of  specific 
(predefined) laborato
ry abnormalities, the central laboratory will alert sponsor personnel 
and the concerned site  personnel . Alert flags that will trigger such notifications are 
displayed in the laboratory manual . 
All laboratory reports must be reviewed, signed and dated by [CONTACT_400416] 10 working days of receipt  and filed with the source documentation. 
The investigator/delegate must indicate on the laboratory report whether abnormal values 
are considered clinically relevant or not. Clinically relevant laboratory findings that are known at the time of signing of informed consent must be recorded on the Medical 
History form of the CRF. Any clinically relevant laboratory abnormalities detected after 
signing  of informed consent must be reported as an AE or SAE as appropriate [see 
Section  9], and must be followed until the value returns to within the normal range or is 
stable, or until the change is no longer clinically 
 relevant. 
ACT -[ADDRESS_504663] 2017, pa ge 55/[ADDRESS_504664] 2017 -003332 -36 
Doc No D-17.029  
Details about the collection, sampling, storage, shipment procedures, and repor ting of 
results and abnormal findings can be found in the laboratory manual. 
[IP_ADDRESS] Laboratory tests 
[IP_ADDRESS].1 Hematology 
â€¢Hemoglobi
n (g/L)
â€¢Hemato
crit (L/L)
â€¢Erythr
ocyte
 count (109/L)
â€¢Leukocyte count with differential counts (109/L)
â€¢Platelet count  (109/L)
[IP_ADDRESS].2 Clinical chemistry
â€¢Alanine aminotran
sferase (U/L)
â€¢Aspartate aminotr
ansferase (U/L)
â€¢Alkaline phosphatase (
U/L)
â€¢Total and direct bili
rubin (Î¼mol/L)
â€¢Creatinine (Î¼mol/L
)
â€¢Creatinine clearance (
eGFR)  estimated with Cockcr oft-Gault formula
â€¢Blood urea nitrogen (mmol/L)
â€¢Uric acid  (Î¼mol/L)
â€¢Total c
holeste
rol (mmol/L)
â€¢Sodium, potassium, chlori
de, calcium (mmol/L)
â€¢Albumin  (g/L)
[IP_ADDRESS].3 Coagulation te
sts
â€¢I
nternational norma
lized ratio
[IP_ADDRESS].[ADDRESS_504665]
â€¢Urin
e pregnancy te
sts
ACT -[ADDRESS_504666] 2017, pa ge 56/[ADDRESS_504667]-STUDY TREATMENT / 
MEDICAL CARE 
8.[ADDRESS_504668] completed the study. 
8.2 Premature withdrawal from study 
Subjects may voluntarily withdraw from the study without justification for any reason at 
any time. Subjects are considered withdrawn if they state an intention to withdraw from 
further participation in all components of the study (i.e., withdrawal of consent), if they 
die, or are lost to follow -up. If a subject withdraws consent, no further data will be 
collected in the CRF from the date of withdrawal onward. The investigator may withdraw a subject from the study (without regard to the subject â€™s consent) if, on balance, he/she 
believes that continued participation in the study would be contrary to the bes t interests of 
the subject. Withdrawal from the study may also result from a decision by [CONTACT_941] s ponsor for 
any reason, including premature termination or suspension of the study. 
Subjects are considered as lost to follow -up if all reasonabl
 e attempts by [CONTACT_42922]. The site must take preventive measures to 
avoid a subject being lost to follow -up (e.g., document different ways of contact [CONTACT_42923], home address, email address, person to be contacte d if the subject 
cannot be reached). If the subject cannot be reached, the site must make a reasonable effort to contact [CONTACT_423], document all attempts, and enter the loss of follow -up 
information into the CRF. The following methods must be used: at le ast [ADDRESS_504669] available home address. Additional methods may be acceptable if they are compliant with local rules/regulations (e.g., a visit by [CONTACT_42926] â€™s home), respecting the subject â€™s right to privacy. If the subject is still 
unreachable after all contact [CONTACT_42927], he/she will be considered to be lost to follow-up. 
If premature withdrawal occurs for an y reason, the reas on 
 (if known) for premature 
withdrawal from the study, along with who made the decision (subject, investigator, or 
sponsor personnel), must be recorded in the CRF, if known. 
If, for whatever reason (except death or loss -to-follow-up), a subject i s withdrawn from 
the study, the investigator should make efforts to schedule a last appointment / telephone 
call to assess the safety and wellbeing of the subject. Data obtained during this last appointment / telephone call will be recorded in the subject â€™s medical records but it will 
not be collected in the CRF. The investigator must provide follow -up medical care for all 
ACT -[ADDRESS_504670] 2017, pa ge 57/[ADDRESS_504671] igators can terminate the participation of their site in the study at any time.  
If a study is prematurely suspended or terminated, the s ponsor /delegate  will promptly 
inform the investiga
tors, the IECs/IRBs, and HAs, as appropriate, and provide the reasons 
for the suspension or termination. 
If the study is suspended or prematurely terminated for any reason, the investigator â€” in 
agreement with the s ponsor â€” must promptly
 inform all enrolled subjects and ensure 
their appropriate treatment and follow -up, as de scribed in Section  8.4. The 
sponsor /delegate  may inform the investi
gator of additional procedures to be followed in 
order to ensure that adequate consideration is given to the protection of the subjects â€™ 
interests.  
In addition, if the investigator suspends or terminates a study without prior agreement 
from the s ponsor , the investigator must prom
ptly inform sponsor personnel and the 
IEC/IRB, and provide both with a detailed written explanation of the termination or suspension. 
If the IEC/IRB suspends or terminates its approval / favorable opi[INVESTIGATOR_1101] a study, the 
investigator must promptly notify s 
ponsor personnel and provide a detailed written 
explanation of the termination or suspension. 
8.4 Medical care of subjects after study completion / withdrawal from study 
The subject â€™s standard of care will not be affected by [CONTACT_28224]. For this PK/PD 
and safety study , subjects will receive [ADDRESS_504672] 2017, pa ge 58/[ADDRESS_504673]-246475. 
AEs include: 
â€¢Exacerbation of a 
pre-existing disease.
â€¢In
crease in frequency or intensity  of a pre -existing epis odic disease or medical
condition.
â€¢Disease or medical condition detected or diagnosed during the course of the study
even though it may have 
been present prior to the start of the study.
â€¢Continuous persistent disease or symptoms pres ent at study start that worsen
following the signing of informed consent.
â€¢Abnormal assessments, e.g., change on physical examination, ECG findings, if they
represent a clinic
ally significant finding that was not present at study start or
worsened during the course of the study.
â€¢Laboratory test abnormalities if they represent a clinically significant finding,symptomatic or not, 
which was not present at study start or worsened during the
course of the study.
Overdose, misuse, abuse of the study treatment and study treatment err ors will be 
reported as an AE . 
9.1.2 Intensity of adverse events  
The intensity of
 clinical AEs is graded on a 3-point scale (mild, m oderate, severe) and is 
reported on specific AE pages of the CRF. 
All changes in intensity of an AE during the study will be reported in the CRF. 
The three categories of intensity are defined as follows:  
ï±Mild
The event may be noticeable to the subject. It does not usually influence daily activities,
and normally does not requir
e intervention.
ï±Moderate
The event may make the subject uncomfortable. Performance of daily activities may beinfluenced, and intervention m
ay be needed.
ACT -[ADDRESS_504674] 2017, pa ge 59/[ADDRESS_504675] 2017 -003332 -36 
Doc No D-17.029  
ï±Severe
The event may cause noticeable discomfort, and usually interferes with daily activities.
The subject may not be able 
to continue in the study, and treatment or intervention is
usually needed.
A mild, moderate, or severe AE may or may not be serious [see Section  9.2.1] . These 
terms are used to describe t
he intensity of a specific event. Medical judgment should be 
used on a case- by-case basis.  
Seriousness, rather than intensity  assessment, determines t he regulatory reporting 
obligations. 
9.1.[ADDRESS_504676] â€™s EOS  telephone call will not be 
collected by [CONTACT_941] s ponsor. 
9.[ADDRESS_504677] one of the 
following criteria:  
â€¢Fatal.
â€¢Life-t
hreatening: Refer
s to an event in whi ch the subject was at ri sk of death at the
time of the event. It does not refer to an event that hypothetically might have caused
death had it been more severe.
â€¢Requiring in-patient hospi[INVESTIGATOR_1081].
â€¢Resulting in persistent o
r significant disability or incapacity.
â€¢Congenital anomaly or birth de
fect.
ACT -[ADDRESS_504678] 2017, pa ge 60/[ADDRESS_504679] 2017 -003332 -36 
Doc No D-17.029  
â€¢Medically significant: Refers to important medical events that may not immediately
result in death, be life -threatening, or require hospi[INVESTIGATOR_400379], based upon appropriate medical judgment, they may jeopardize thesubject, and may require medical or surgical intervention to prevent one of theoutcomes listed in the definitions above.
The following reasons for hospi[INVESTIGATOR_42863]:  
â€¢Hospi[INVESTIGATOR_180458], or social and/or convenience reasons
(including hospi[INVESTIGATOR_400380]).
â€¢Hospi[INVESTIGATOR_5912] -planned (i.e., planned p rior to signing informed consent)
surgery or  standard monitoring of a pre -existing disease or medical condition that did
not worsen, e.g., hospi[INVESTIGATOR_42865] a subject with stable
angina pectoris.
However, complications that occur during hospi[INVESTIGATOR_42866] (e.g., if a complication prolongs hospi
[INVESTIGATOR_059]). 
9.2.[ADDRESS_504680] a 
reasonable possibility of a causal relationship to either the study design or to 
protocol- mandated procedures (e.g.,  discontinuation of a subject â€™s previous treatment 
during a washout period leading to exacerbation of underlying disease). All SAEs must be reported by [CONTACT_238977] s ponsorâ€™s G lobal Drug Saf
 ety 
department within 24 hours of the investigatorâ€™s first knowledge of the event. All SAEs must be recorded on a SAE form, irrespective of the study treatment received 
by [CONTACT_423], a
nd whether or not this event is considered by [CONTACT_400417].  
The SAE forms must be sent to the s ponsorâ€™s Global Drug Safety department (contact 
[CONTACT_180514]). The investigator must complete the SAE form in 
English, and must assess the eventâ€™ s causal relationship to the study treatment.  
Any relevant information from source documents regarding the SAE, e.g., hospi[INVESTIGATOR_400381]
s, etc., must be summarized on the SAE form.  
ACT -[ADDRESS_504681] 2017, pa ge 61/[ADDRESS_504682] also be reported within 
24 hours of receiving it. The s ponsorâ€™s Global Drug Safety personnel may contact [CONTACT_110198]. 
If the subject is hospi[INVESTIGATOR_42868] a hospi[INVESTIGATOR_42869], it is the investigator â€™s 
responsibility to con
tact this hospi[INVESTIGATOR_42870] -relevant information and 
documentation. The expectedness of an adverse reaction is determined by [CONTACT_941] s ponsor in the referenc
 e 
safety information (RSI) section provided in the most recent version of the IB. Any SAE 
that is assessed as related and unexpected against the RSI is known as a S[LOCATION_003]R and must 
be reported by [CONTACT_941] s ponsor/delegate to concerned HAs (including the EudraVigilance 
database if the study is conducted in Europe), IECs/IRBs and investigators. 
9.2.[ADDRESS_504683]â€™s EOS  telephone cal l must be 
reported to the s ponsorâ€™s Global Drug Safety department, but it is not recorded in the 
CRF.  
9.2.[ADDRESS_504684] be reported to the s ponsorâ€™s 
Global Drug  Safety department within 24  hours of the investigator â€™s knowledge of the 
event, only if considered by [CONTACT_259164].  
9.[ADDRESS_504685] and discuss the risks of continuing with the pregnancy and the possible effects 
on the fetus. 
9.3.1 Reporting of pregnancy  
Any pregnancy occurring  after study start ( i.e., signing of informed consent) up to 
[ADDRESS_504686] be reported within 24 hours of the 
investigator â€™s knowledge of the event. 
Pregnancies must be reported on the Pregnancy form, which is faxed to the s ponsorâ€™s 
Global D rug Safety 
department (see contact [CONTACT_42936]), and 
on an AE page in the CRF. 
ACT -[ADDRESS_504687] 2017, pa ge 62/[ADDRESS_504688] be 
reported to the s ponsorâ€™s Global Drug Safety department.  
Any AE associated with the pregnancy occurring during the follow -up period after study 
treatment  administra
tion must be reported on separate AE pages in the CRF. Any SAE 
occurring during the pregnancy must be reported on a n SAE form as described in 
Section  9.3.1. 
9.4 Study safety monitoring 
Study safety information (AEs, SAEs, laboratory values, ECGs, vital signs, and 
study- specific examinations as required) is monitored and reviewed on a continuous basis 
by [CONTACT_456]â€™s c linical team (in charge of ensuring subjects â€™ safety as well as data 
quality). In addition, a Safety Event Committee  is monitoring safety data 
[see S ection  3.4]. 
10 STATISTICAL METHODS 
All s tatistical analyses will be conducted by [CONTACT_941] s ponsor or by [CONTACT_400418] s ponsor. 
A statistical analysis plan (SAP) will provide full details of  the analyses, data displays, 
and algorithms to be used for data derivations. 
Any deviation(s) from the original statistical plan described hereafter will be described 
and justified in the SAP or in the CSR, as appr
opriate. 
10.[ADDRESS_504689] been assigned to a 
double- blind study treatment.  
10.1.3 Full analysis
 set 
The Full analysis set (FAS) includ
es all  randomized sub jects who have been administered  
the study treatment.  
ACT -[ADDRESS_504690] 2017, pa ge 63/[ADDRESS_504691] 2017 -003332 -36 
Doc No D-17.029  
In order to adhere to the intention- to-treat principle as much as possible:  
â€¢Subjects are evaluated according to the study treatment th ey have been assigned to
(which may
 be different from the study treatment they have received),
â€¢All available data are included.
10.1.4 Per-protocol analysis s et 
The Per-protocol s e
t (
PPS) comprises all subjects from  the FAS who complied with the 
protocol sufficie ntly to allow adequate estimation of the treatment effects. Criteria for 
sufficient compliance include exposure to treatment, availability of key endpoints 
measurements and absence of major protocol deviations that have an impact on the 
treatment effect.  
The full list of criteria will be detailed in the SAP before making the full randomization 
information available.  
10.1.5 Safety s et 
The Safety
 set (SS) includes all subjects wh
o rec eived study treatment.  Subjects will be 
evaluated according to the actual treatment  they received, which may differ from the 
randomly assigned treatment. 
10.1.[ADDRESS_504692] 2017, pa ge 64/[ADDRESS_504693] disposition  X 
Baseline and disease characteristics  (x) X (x) 
Previous and concomitant medication  X
Study treatment  exposure  X (x) 
PD endpoints analyses  X (x) 
Safety and tolerability analyses  X 
PK data analysis  X 
Note : Selected safety parameters,  X: main analysis, (x): Sensitivity analysis to be conducted only if > 10% difference 
of set size w ith set used for main analysis. 
FAS,  Full analysis set; PD, Pharmacody namic; PK, Pharmacokinetic; PPS, Per-protocol set; RND, Randomized set ; 
SS, Safety set. 
10.[ADDRESS_504694] 2 values collected during the screening phase prior to randomization. 
10.2.1 Primary efficacy variable(s)  
Not applicable.  
10.2.2 Key s
econdary efficacy variables 
Not applicable.  
10.2.3 Safe
ty variables 
[IP_ADDRESS] Adverse events  
An AE  is d
efined as an
y event that is recorded on the AE CRF module regardless of the 
onset date.  
TEAEs  are tho
se AEs with onset date/time  â‰¥ d ate/time of first study treatment 
administration and â‰¤ 48 h after date/time  of last study treatment administration . 
The handling of missing or incomplete date/time of AEs and assessments will be 
described in the SAP. 
ACT -[ADDRESS_504695] 2017, pa ge 65/[ADDRESS_504696] 2017 -003332 -36 
Doc No D-17.029  
[IP_ADDRESS] Laboratory data 
Laboratory analyses are based on data received from the central laboratory  
[see S ection  [IP_ADDRESS]] . All transferred centr
al laboratory data are taken into account 
regardless of whether they corr
espond to scheduled or unscheduled assessments. 
Baseline laboratory test refers to the latest lab oratory test performed prior to t he first 
study treatment administration .  
End-of-treatment laboratory test refers to t he laboratory test performed on the day 
following the day of study treatment administration (Visit 3) . 
For each continuous laboratory parameter, the following variables will be summarized: 
â€¢Absolute value at each time point,
â€¢Absolute change from baseline to ea
ch time point,
â€¢Treatment -emergent marked laborator
y abnorm alities (i.e., up to 48 h after study
treatment administration) .
For categorical laborator y parameters, the following var iables will be summarized: 
â€¢Proportion of subjects by [CONTACT_400419].
Unless stated otherwise, no imputati
on for missing laboratory values will be performed.
[IP_ADDRESS] ECG  
ECG recording  is performed at the time points described in  Table 3. 
â€¢Treatment -emergent ECG abnormalities (i.e., up to 48 h after study treatment
administration ).
â€¢Absolute c hange from baseline to each time p oint in ECG variables: HR, and the
intervals: PQ/PR,  QRS, QT, RR, QTcB, and QTcF.
[IP_ADDRESS] Vital signs  
â€¢Absolute value in vital signs at each a
ssessed time point during the study.
â€¢Rel
ative change from baseline to each measured time point in vital signs (systolic and
diastolic arterial BP and pulse rate).
10.2.4 Pharm
acokinetic and pharmacodynamic  variables  
[IP_ADDRESS] Pharmacokinetic variable
s 
Plasma concentrations per time po
int will be listed by [CONTACT_400420], and 
summarized by [CONTACT_400421], 
ACT -[ADDRESS_504697] 2017, pa ge 66/[ADDRESS_504698] deviation (SD), standard error (SE), and 2-sided 
95% confidence interval ( CI) of the means and coefficient of variation (CV) in %. 
PK parameters will be derived using non-compartmental methods: 
â€¢Cmax, tmax, and AUC 0â€“24h will be listed by [CONTACT_400422].
â€¢Cmax, tmax*, and AUC 0â€“24h will be summarized with arithmetic mean, geometric mean,
minimum, median, maximum, SD, SE, CV (%), and 95% CI of the arithmetic and
geometric means.
(* For t max the geometric mean and its 95% CI will not be calculated).
â€¢Log-transformed C max and AUC 0â€“24h values will be summarized with mean and SD of
the logs.
[IP_ADDRESS] Pharmacodynamic variables 
The primary PD variable is the IP
A as measured by  [CONTACT_87253]Â® at each time  point, as 
described in  table of assessments  [Table 2 and Table 3]. 
The primary PD endpoint is the PD response  that is defined for each subject as a 
PRU  < [ADDRESS_504699] 3 h, as measured via 
VerifyNowÂ®. 
Additional PD variables related to the main ones will also be considered  at each time 
point: 
â€¢Extent  of aggregation (me
asured through LTA).
â€¢A
bsolut e PRU values  (for VerifyNowÂ®).
â€¢% of subjects at 8 h after study treatment  injection with PRU value < 100 or
> 1.05 Ã— baseli
ne value.
10.[ADDRESS_504700] 1 of the 2 active arms,  it 
will be completed by [CONTACT_400423] a 
response is statistically greater than 70%.  
ACT -[ADDRESS_504701] 2017, pa ge 67/[ADDRESS_504702] 1 of the 2 active arm s, the 2 null hypothes es are sequentially rejected at an adju sted 
alpha level of 0.025. 
No imputation will be considered for handling missing values in the main analysis of PD. 
Imputation s may be perfor
med in sensitivity /exploratory analyses, if deemed necessary, 
e.g., if more than 10% missing values at a given time point.
10.3.[ADDRESS_504703] -246475 treatment enables a large 
proportion ( a target of 85% ) of the enrolled subjects to achieve a clinically meaningful  
level of IPA, i.e. , PRU < 100. 
[IP_ADDRESS] Hypotheses and statistical model 
The primary goal is 
to determine that the proportion p of subjects  receiving a dose of 
ACT -246475, who achieve the PD  response as measured by [CONTACT_87253]Â®, is statistically 
greater than 70%. 
In order to achieve this objective, the testing strategy will consider a sequentia l 
approach  demonstrate  a statistically  significant difference between  the control arm 
(placebo) and  at least 1 of the active arms, then to confirm that the observed response rate 
(Pr) in the same active arm is statistically significantly greater than the predefined 
response rate.  
The comparison of each of the 2 active treatment arms will be conducted vs placebo , with 
the following hypothese s:  
Hp0HD: pplacebo  = p HD 
vs 
Hp1HD: pplacebo  â‰  p HD 
AND  
Hp0LD: pplacebo  = p LD 
vs 
Hp1LD: pplacebo  â‰  p LD
Where, pplacebo  is the proportion of responders in Placebo arm, pHD is the proportion of 
responders in the ACT -[ADDRESS_504704] 2017, pa ge 68/[ADDRESS_504705] at an overall 
significance level (alpha) of 0.05 adjuste d for multiplicity using the Bonfer roni method, 
i.e., 0.025 for each comparison.
Assuming that either  Hp0HD, or H p0LD, or both are rejected, then the following hypotheses  
will be tested for each of the active doses  that were statistically significantly dif ferent 
from  placebo :  
H0: Presponders  = 0.70  
vs  
H1: Presponders  > 0.[ADDRESS_504706] at an ove rall 
significance level (alpha) of 0.05 adjusted for multiplicity using the Bonfer roni method , 
i.e., 0.025 for each comparison.
[IP_ADDRESS] Handling of missing data 
Subject s for wh om determ
ination of the response is not possible will be counted a s 
non-responders in the main analysis ; no other imputation will be considered . 
[IP_ADDRESS] Main analysis 
The primary statistic
al analysis will be performed on the FAS population  for each dose 
level.  
Th
e first set of null hypothese s (Hp0HD and H p0LD) will be tested for each dose by a 
2-sided z -test at an overall significance level (alpha) of 0.05 adjusted for multiplicity
using the Bonferroni method, i.e., 0.025 for each comparison.
The second null hypothesis (H 0) will be tested for each dose by a 1-sided z -test. The 
estimated proportion of responders in each arm and the corresponding 95% CI will be 
provided.  A longitudinal analysis of the treatment effect, from start of treatme
 nt up to 8 h after 
injection, on platelet reactivity  as measured by [CONTACT_87253]Â®, i.e., PRU value, will be 
performed using a mixed model with PRU as the dependent variable, subject as a random 
factor, and treatment ( 8 mg, 16 mg , and placebo), injection site (abdomen, thigh), PRU 
level at randomization (stratification levels), age (continuous), gender (male, female), and 
assessment time (continuous) as fixed factor s. The model will also include (treatment  Ã— 
injection site)  as an interaction term to assess consistency of treatment effect across 
injection sites.  
A logistic regression analysis of the PD response will be performed using the same factor as covariates.  
ACT -[ADDRESS_504707] 2017, pa ge 69/[ADDRESS_504708] 2017 -003332 -36 
Doc No D-17.029  
Summary of PD response, i n term s of number (%) of subjects , will be provided. IPA as 
measured by [CONTACT_87253]Â® will also be summarized as a continuous parameter. 
[IP_ADDRESS] Supportive/sensitivity analyses  
The consistency acr
oss the following  subgroups will be asse ssed by [CONTACT_400424], assuming there are a sufficient  number of subjects: 
1. Age: < 55 vs â‰¥ 55 years
2. Body mass index: < 25.0 vs
 (â‰¥ 25.0 and < 30.0) vs â‰¥ 30.0 kg/m2
3.Sex: mal
e vs female
4.Diabetes  mellitus  at base
line: yes vs no
5. Chronic kidney disease: yes vs noAn additional analysi
s of the supportive PD endpoint (LTA -PD response) wil l be 
conducted using the same approach as described for the primary PD analysis.  
Further analyses will be described in the SAP as necessary.  
10.3.3 Analysis of key secondary efficacy variable(s) 
Not applicable.  
10.3.4 Anal
ysis of the safety variables 
Unless noted otherwise
, the SS will be used for summaries and listings of safety data. 
[IP_ADDRESS] Adverse events  
AEs coded using the
 most recent version of MedDRA, will be summarized (frequency 
counts and percentages) 
by [CONTACT_5379]/or preferred term, and maximum 
intensity.  
Summaries will be provided  for the following data : 
â€¢TEAEs.
â€¢TEAEs related to
 study treatment.
â€¢Treatment -emergent non -se
rious AEs.
â€¢Treatment -emergent SAEs.
â€¢Treatm
ent-emergent SAE s related to study treatment.
â€¢TEAE s with fatal outcome.
â€¢TEAEs related to
 study treatment with fatal outcome .
ACT -[ADDRESS_504709] 2017, pa ge 70/[ADDRESS_504710] 2017 -003332 -36 
Doc No D-17.029  
[IP_ADDRESS] Laboratory data 
Unless noted otherwise, summaries and listings will include unscheduled assessments 
reported by [CONTACT_400425]. 
Descriptive  summary statisti cs by [CONTACT_400426] . 
The absolute change from baseline to each time point  for hematology and bl
 ood 
chemis try variables  will be summarized.  
Number (%) of subjects with treatment- emergent marked lab oratory abnormalities will be 
tabulated and all marked laboratory abnormalities will be listed.  
[IP_ADDRESS] Vital signs, weight and physical examination 
Each summary and
 listing  will include unscheduled a ssessments. 
Absolute changes from baseline to last value on study treatment in vital signs will be summarized. The ab
solute values at each time point will also be summarized.  
Physical examination abnormalities will be listed.  
[IP_ADDRESS] Electrocardiograms 
Each EC
G summary and listing will include unscheduled assessments. 
The absolute change from baseline to each time point  for ECG variables  will be 
su
mmarized. The absolute values at each time point will be summarized.  
Number (%) of subjects having a marked ECG abnormality during the treatment period will be summarized.  
All EC
G values for subjects with at least one marked ECG abnormality will be listed. 
10.4 Interim analyses 
No interim analysis planned. 
10.5 Sample size  
The sample size is based on the primary PD endpoint, which  is the proportion of subjects 
achieving a predefined PD response as measured by [CONTACT_87253]Â®. The computation of the 
sample size was performed using the East 6.0 software (version [IP_ADDRESS], 30 Aug. 2016) from Cytel.  
This study inclu des 3 treatment arms , 2 active ar
 ms (ACT -246475 8 mg and 16 mg) and a 
placebo arm comprising the [ADDRESS_504711] 2017, pa ge 71/[ADDRESS_504712] 1 of the  2 doses has a 
higher response rate than placebo and that this response rate is statistically  significantly  
greater than the proportion of responders under H 0. 
The sample size required for demonstrating a difference to placebo is based on an overall  
alpha of 0.05 (2- sided )
, adjusted for multiplicity using a Bonfer roni method to 0.025 for 
each comparison, and a power  of 0.9; the assumptions related to response rate under the 
null and alte rnative hypotheses  are reported in the table below: 
Proportion of 
responders under H 0 
(placebo)  Proportion of 
responders under H 1 
(active)  Number of subjects  
(total)  Number of 
subjects  
(per arm)  
50% 75% 
(odds ratio of 3)  288 96 
The samp
le size required to demonstrate that the achieved res ponse rate is diffe rent from 
70% is based on a 2-sided type I error (alpha) of 0.025, and a power of 0.9; the 
assumptions related to response rate under the null and alternative hypotheses, are 
reported in the table below: 
Proportion of 
responders under H 0 Proportion of 
responders under H 1 Number of subjects  
(total for the 2 active 
arms)  Number of 
subjects  
(per arm)  
70% 85% [ADDRESS_504713] 98  subjects evaluable fo r the primary PD 
endpoint in each treatment arm . Assuming a rate of drop- out or non- evaluable data of 
about 10%, each arm will include 108 subjects leading to a total for the study of 
324 subjects.  
11 DATA HANDLING 
11.1 Data collection 
The investigator/delegate is responsible for maintaining adequate and accurate source documents and trial records that include all pertinent observations on each of the site â€™s 
trial subjects.  
ACT -[ADDRESS_504714] 2017, pa ge 72/[ADDRESS_504715] be consistent with the 
source documents. 
CRF data will be captured via electronic data capture (using the Rave system provided by 
[CONTACT_400427], Inc. , a web -based tool). The investigator and site personnel will be 
trained to enter and edit the data via a secure network, with secure access features 
(username, password, and identification â€” an electronic password system). A complete 
electronic audit trail will be maintained. The investigator/delegate will approve the data (i.e., confirm the accuracy of the data recorded) using an electronic signature (ref. to  US 
21 CFR Part 11). 
Subject screening and randomization data will b
 e completed for all subjects (i.e.,  eligible 
and non- eligible) through the IRT system and CRF.  
For each subject screened (i.e. , who signed an ICF), r egardless of study treatment 
administration , a CRF must be completed and signed by [CONTACT_093]/delegate. This 
also applies to those subjects who fail to complete the study. If a subject withdraws from 
the study, the reason must be noted on the CRF. 
11.2 Maintenance of data confidentiality 
The investigator/delegate must ensure that data confidentiality is maintained. On CRFs or 
other documents (e.g., documents attached to SAE forms / Pregnancy forms ) submitted to 
the sponsor and any CROs , subjects must be identified only by [CONTACT_400428], date of bir th, hospi[INVESTIGATOR_42871], or any other identifier. The 
investigator/delegate must keep a subject identification code list at the site, showing the screening/randomization number, the subject â€™s name, date of birth, and address or any 
other locally accepted iden tifiers. Documents identifying the subjects (e.g., signed ICF) 
must not be sent to the s ponsor , and must be kept in strict confidence by [CONTACT_1275]/delegate.  
11.[ADDRESS_504716] status at any time point during the course of the study. 
While entering the data, the investigator/delegate will be instantly alerted to data queries by [CONTACT_400429]. Additional data review will be performed by 
[CONTACT_3211] /delegate  personnel on an ongoing basis to look for unexpected patterns in data 
and for study monitoring. If discrepant data are detected, a query specifying the problem and requesting clarification will be issued and visible to the investigator/delegate via the CRF. All electronic queries visible in the system either require a data c orrection (when 
applicable) and a response from the investigator/delegate to clarify the queried data 
ACT -[ADDRESS_504717] 2017, pa ge 73/[ADDRESS_504718] 2017 -003332 -36 
Doc No D-17.029  
directly in the CRF, or simply a data correction in the CRF. The investigator/delegate 
must, on request, supply the s ponsor with any required background d ata from the study 
documentation or clinical records. This is particularly important when errors in data transcription are suspected. In the case of HA queries, it is also necessary to have access 
to the complete study records, provided that subject confidentiality is protected.  
This process will continue until database closure. 
Laboratory samples and ECGs will be processed t
 hrough a central vendor and the results 
will be electronically sent to the sponsor. 
AEs are coded according to the latest MedDRA  used by [CONTACT_456]. 
After 
the database has been declared complete and accurate, the database will be closed. 
Any changes to the 
database after that time may only be made as described in the 
appropriate sponsor QS docs. After database closure, the investigator will receive the 
CRFs of the subjects of his/her site (including all data changes made) on electronic media 
or as a paper copy.  
12 PROCEDURES AND GOOD CLINICAL PRACTICE 
12.1 Ethics and Good Clinical Practice 
Sponsor /delegate personnel and the investigators will ensure that the study is conducted 
in full compliance with this protocol, ICH-GCP Guidelines, the principles of the 
â€˜Declaration of Helsinki â€™, and with the laws and regulations of the country in which the 
study is conducted. 
12.2 Independent Ethics Committee / Institutional Review Board 
The investigator will submit this protocol and any related document(s) provided to the subject (such as the ICF) to an IEC/IRB. Approval from the committee/board must be obtained before starting the study, and must be documented in a dated letter to the 
investigator, clearly identifying the study, the documents reviewed, and the date of approval. 
Modifications made to the protocol or the ICF after receipt of the approval must also be 
submitted as amendmen
ts by [CONTACT_249303] e IEC/IRB in accordance with local 
procedures and regulations. 
A list of members participating in the IEC/IRB meetings must be provided, including the 
names, qualifications, a
nd functions of these members. If that is not possible, the attempts 
made to obtain this information along with an explanation as to why it cannot be obtained or disclosed must be documented in the study documentation.  
ACT -[ADDRESS_504719] 2017, pa ge 74/[ADDRESS_504720] 2017 -003332 -36 
Doc No D-17.029  
If a member of the study personnel was present during an IEC/IRB meeting, it must be 
clear that this person did not vote.  
12.3 Informed consent  
It is the responsibility of the investigator/delegate to obtain informed consent according to ICH -GCP and Declaration of Helsinki guidelines and local regulations from each 
individual participating in this study and/or legally designa ted representative. The 
investigator/delegate must explain to subjects that they are completely free to refuse to enter the study, or to voluntarily withdraw from the study at any time for any reason without having to provide any justification. Special attention shall be paid to the information needs of specific subject populations and of individual subjects, as well as to the methods used to give the information. Adequate time shall be given for the subject and/or legally designated representative to consi der his or her decision to participate in 
the study and it shall be verified that the subject has understood the information (e.g., by [CONTACT_208287]). 
The ICF will be provided in the country local language(s). 
Site p ersonnel authorized to participate in the consent process and/or to obtain consent 
from the subject a
nd/or legally designated representative will be listed on the Delegation 
of Authority form supplied by [CONTACT_941] s ponsor /delegate . A study physician must always be 
involved in the consent process. 
The subject and/or legally designated representative and authorized site personnel listed 
on the Delegation of 
Authority form supplied by [CONTACT_941] s ponsor /delegate  must sign, 
personally date, and time (if the first study -mand ated procedure is to be performed on the 
same day informed consent is obtained) the ICF before any study -related procedures 
(i.e., any procedures required by [CONTACT_760]) begin.  
A copy  (or a second original)  of the signed and dat ed ICF is given to the subject and/or 
legally designated representative; the original is filed in the site documentation. The 
informed consent process must be fully documented in the subject â€™s medical records. 
This must include, at a minimum, the study reference, the subject number, the date and the information that a copy of the signed ICF was given to the subject/legally designated representative. Where applicable, this must also include the time and date when the subject was first introduced to the study, the time of consent, who participated in the consent discussion, who consented the subject and any additional person present during the consent process (e.g., the subjectâ€™ s family member[s])  
If the site intends to recruit subjects w ho are considered vulne
 rable (e.g., subject cannot 
read or write, or does not speak or understand the ICF language), additional measures 
must be implemented in order to ensure subject â€™s rights are respected and the consent 
ACT -[ADDRESS_504721] 2017, pa ge 75/[ADDRESS_504722] 2017 -003332 -36 
Doc No D-17.029  
obtained is legally valid. The s ponsor , the regulatory authorities (if applicable), and the 
IEC/IRB must be informed prior to the recruitment. The consent process (e.g., 
involvement of an impartial witness) must be fully described, submitted to, and approved by [CONTACT_6179]/IRB, according to procedures and before subjects are recruited. 
12.4 Compensation to subjects and investigators 
The s ponsor provides insurance in order to indemnify (with both legal and financial 
coverage) the investigator/site against claims arising from the study, except for cl aims 
that arise from malpractice and/or negligence.  
The compensation of the subject in the event of study -related injuries will c omply with 
applicable regulations. 
There is no direct health benefit for the subj ects participating  in the study. Accordingly, 
subject s may receive financial compensation for the time spent in the clinical trial in 
compliance with local regulation.  
12.5 Protocol adherence/compliance 
The investigator must conduct the study in compliance with the IEC/IRB and/or the 
regulatory authority -approved version of the protocol and must not implement any 
deviation/change from the protocol, except when deviation is necessary to eliminate an immediate hazard to the subject.  
If a protocol deviation occurs, the investigator/ delegate will inform the
  sponsor or its 
representative in a timely manner. The investigator/delegate must document and explain any deviation from the approved protocol. Deviations considered to be a violation of ICH-GCP must be reported to the IEC/IRB and regulatory authorities according to the 
sponsor or (overruling) local requirements. 
All protocol deviations will be reported in the CSR. IECs/IRBs will be provided with 
listings of protocol devia
tions as per local requirements. 
12.[ADDRESS_504723] be submitted to the IEC/IRB and regulatory authorities, in 
accordance with local regulations and procedures.  
12.7 Essential documents and retention of documents 
The investigator/delegate must maintain adequate records necessary for the reconstruction and evaluation of the study. A number  of attributes are considered of 
universal importance to source data and the records that hold those data. These include that the  source data and records are attributable, legible, contemporaneous, original  
ACT -[ADDRESS_504724] 2017, pa ge 76/[ADDRESS_504725] 2017 -003332 -36 
Doc No D-17.029  
(or certified copy), accurate, and complete. Changes to source data and records must be 
traceable, must not obscure the original entry and mus t be explained if necessary 
(e.g.,  via an audit trail).   
These records are to be classified into 2 different categories  of documents: ISF and 
subjects â€™ source documents. 
These records must be kept by [CONTACT_400430] s ponsorâ€™ s requirement
s (i.e ., as specified in the clinical study agreement), and 
national and/or international regulations, whichever would be the longest period. If the investigator cannot guarantee this archiving requirement at the site for any or all of the documents, special arrangements, respecting the data confidentiality, must be made between the investigator and  the s ponsor to store these documents outside the site, so that 
they can be retrieved in case of a regulatory inspection. No study document should be destroyed without  prior written approval from the s ponsor . Should the investigator wish 
to assign the study records to another party, or move them to another location, the 
sponsor must be notified in advance. 
If the site is using an electronic/computerized system to store subject medical records, it 
can be used for the pu
rpose of the clinical study if it is validated (as per [ADDRESS_504726]) and if the CRA  has been provided personal and restricted 
access to study subjects only, to verify consistency be tween electronic source data and 
the CRF during monitoring visits. 
If the site is using an electronic/computerized system to store subject medical records but 
it could not be confirm
ed that the system is validated or if the CRA  could not be provided 
access  to the system, the site is requested to print the complete set of source data needed 
for verification by [CONTACT_2689] . The printouts must be numbered, stapled together with a 
coversheet, signed and dated by [CONTACT_093]/delegate to confirm that these certi fied 
copi[INVESTIGATOR_400382]. The 
printouts will be considered as the official clinical study records and must be filed either with the subjectâ€™s medical records or with the subjectâ€™ s CRF.  
In orde r to verify that the process the site uses to prepare certified copi[INVESTIGATOR_42874], the 
CRA  must be able to obs 
erve this process and confirm that the comparison of the source 
documents and the certified copy did not reveal inconsistencies. The CRA  does not  need 
to verify this process for all data of all subjects but at least for some of them (e.g., first subject; regular check during the study of critical data like inclusion/exclusion criteria, endpoints for some subjects) as per the s ponsorâ€™ s instructions. If it were not possible for 
the CRA  to observe this process, it would not be possible to rely on the site â€™s certified 
copi[INVESTIGATOR_180462].  
ACT -[ADDRESS_504727] 2017, pa ge 77/[ADDRESS_504728] 2017 -003332 -36 
Doc No D-17.029  
12.8 Monitoring 
Prior to study start, a site initiatio n visit (SIV) will be performed after the required 
essential study documents are approved by [CONTACT_400431]. The study treatment 
will be shipped to the site upon approval of the required essential documents. 
The principal investigator ( PI) must en sure that a ll site personnel involved in the study 
are present during the SIV and will dedicate enough time to it.  
The SIV must be completed before the site can start the screening of study subjects. 
Following the SIV, a
 copy of the completed initiation visit report and follow -up letter 
will be provided to the PI [INVESTIGATOR_42876]. 
During the study, the CRA will contact [CONTACT_42947], 
on request, to have acce
ss to study facilities and all source documents needed to ve rify 
adherence to the protocol and the completeness, consistency, and accuracy of the data being entered in the CRFs and other protocol -related documents. Sponsor monitoring 
standards require full verification that informed consent has been provided, verif ication 
of adherence to the inclusion/exclusion criteria, documentation of SAEs, and the recording of the main PD, safety, and tolerability endpoints. Additional checks of the 
consistency of the source data with the CRFs will be performed according to the study- specific monitoring guidelines. The frequency of the monitoring visits will be 
based on subject recruitment rate and critical data- collection times.  
The PI [INVESTIGATOR_400383] a subject â€™s visit (site visit or 
t
elephone call), and that all requested subject files (e.g., ICFs, medical notes/charts, other 
documentation verifying the activities conducted for the study) are available for review by [CONTACT_2689]. The required site personnel must be available during monitoring visits and allow adequate time to meet with the CRA to discuss study -related issues.  
The investigator agrees to cooperate with the CRA (s) to ensure that
  any issues detected in 
the course of these monitoring visits are resolved. If the subject is hospi[INVESTIGATOR_42878]  
a hospi[INVESTIGATOR_42869], the investigator is responsible for contact[CONTACT_42948][INVESTIGATOR_215185], in accordance with local regulations. 
A close- out visit will be performed for any initiated site when there are no more active  
subjects and all f
ollow -up issues have been resolved. If a site does not enroll any 
subjects, the close -out visit may be performed prior to study database closure at the 
discretion of the s ponsor. 
ACT -[ADDRESS_504729] 2017, pa ge 78/[ADDRESS_504730] be kept by [CONTACT_180535], ICH -GCP, as well as instructions from the s ponsor . If the site needs to 
transfer the ISF to another location and/or if site facility can no longer store the ISF, the PI [INVESTIGATOR_400384]. 
If the PI [INVESTIGATOR_208165], or if the site will relocate, the CRA  must be notified as 
 soon as 
possible. 
12.10  Audit  
The s ponsorâ€™ s QA representatives may audit the investigator site (during the study or 
after its completion). The purpose of this visit will be to determine the investigator â€™s 
adherence to ICH -GCP, the protocol, and applicable regulations; adherence to the 
sponsorâ€™s requirements (e.g., standard operating procedures) will also be verified. Prior to initiating this audit, the investigator will be contact[CONTACT_400432] /delegate  to arrange a 
time for the audit.  
The investigator and site personnel must cooperate with the auditor(s) and allow access to all study documentation (
e.g., subject records) and facilities. 
12.11  Inspections 
HAs and/or IEC s/IRB s may also conduct an inspection of this study (during the study or 
after its completion) at the site.  
Should an inspection be  announced by a HA and/or IE C/IRB, the investigator must 
immediately inform the sponsor (usually via the CRA) that such a request has been made.  
The investigator and site personnel must cooperate with inspector(s) and allow access to all study documentatio n (e 
.g., subject records) and study facilities. 
ACT -[ADDRESS_504731] 2017, pa ge 79/[ADDRESS_504732] 2017 -003332 -36 
Doc No D-17.029  
12.12  Reporting of study results and publication 
The s ponsor /delegate will post the key elements of this protocol and the summary of 
results within the required timelines on publically accessible databases 
(e.g.,  clinicaltrials.gov, EU database), as required by [CONTACT_42951]. 
Study results will be documented in a CSR that will be signed by [CONTACT_400433] t
he Coordinating Investigator. 
In accordance with the Good Publication Practices and ethical practice, the results of the study will be submitted
 for publication in a peer -reviewed journal. Study results can be 
submitted for presentation at a congress before submission to a peer-reviewed journal. 
The Coordinating Investigator [INVESTIGATOR_400385], if any, will ha ve the 
opportunity to review the analysis of the data and to discuss the interpretation of the 
study results with the sponsor personnel prior to submission to a peer -reviewed journal or 
presentation at a congress.  
Authorship will be determined in accordance with the International Committee of Journal Editors criteria, and b
e based on: 
â€¢substantial contributions to the conception or design of the study, or the acquisition,
analysis, or interpr
etation of data; and
â€¢drafting of the publication or critical review for important intellectual content; and
â€¢providing final approval
 of the version to be published; and
â€¢agreement to be a
ccountable for all aspects of the work in ensuring that questions
related to the accur
acy or integrity of any part of  the work are appropriately
investigated and resolved.
The list of authors of any publication of study results may include representatives of the 
sponsor and will be de
termined by [CONTACT_11402].  
Any study- related publication written independently by [CONTACT_400434] s ponsor for review
 at least [ADDRESS_504733] alterations and/or deletions for the sole purpose of protecting its confidential 
information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period. 
The s ponsorâ€™s Policy on Scientific Publications can be found at: 
https://www.idorsia.com/documents/com/policies -charters/policy -scientific -
publications.pdf 
ACT -[ADDRESS_504734] 2017, pa ge 80/[ADDRESS_504735] 2017 -003332 -36 
Doc No D-17.029  
13 REFERENCES 
[ACT -246475 IB] ACT -246475 Investigator â€™s Brochure  Version 3. Idorsia 
Pharmaceuticals Ltd, July 2017. 
[Amlani 2010] Amlani S, Nadarajah T, Afzal R, Pal-Sayal R, Eikelboom J W, 
Natarajan  MK. Mortality and morbidity following a major bleed in a registry 
population with acute ST elevation myocardial infarction. J Thromb Thrombolysis 
2010;30:434â€“40. 
[Amsterdam  2014] Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, 
Homes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with 
non-ST-elevation acute coronary syndromes: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130:e344â€“426. 
[Andre 2003] Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, 
et al. P2Y12 regulates 
platelet adhesion/activation, thrombus growth, and thrombus 
stability in injured arteries. J Clin Invest 2003;112:398-406. 
[Andre 2011] Andre P, Deguzman F, Haberstock- Debic H, Mills S, P ak Y, Inagaki M, et 
al. Thienopyridines, but not elinogrel, result in off -target effects at the vessel wall 
that contribute to bleeding. J Pharmacol Exp Ther 2011;338:22â€“30. 
[Becker  2010] Becker RC, Gurbe l PA. Platelet P2Y12 receptor antagonist 
pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipat ed risk for platelet -directed therapi[INVESTIGATOR_014]. Thromb 
Haemost 2010;103:535â€“44. 
[Beygui 2015] Beygui F, Castren 
 M, Brunetti ND, Rosell -Oritz F, Christ M, Zeymer U, 
et al. ACCA study group on pre -hospi[INVESTIGATOR_10422]. Pre -hospi[INVESTIGATOR_400386]/or dyspnoea of cardiac  origin. A position paper of the Acute 
Cardiovascular Care Association (ACCA) of  the ESC. Eur Heart J Acute 
Cardiovasc Care. 2015 Aug 27. 
[DavÃ¬  2007] DavÃ¬ G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 
2007;357:2482â€“94. 
[Davies  1986] Davie
s MJ, Thoma s AC, Knapman PA, Hangartner JR. Intramyocardial 
platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986;73:418â€“27. 
[Dorsam  2004] Dorsam RT, Kunapul
 i SP. Central role of the P2Y12 receptor in platelet 
activation. J Clin Invest 2004;113:340â€“5. 
ACT -[ADDRESS_504736] 2017, pa ge 81/[ADDRESS_504737] 2017 -003332 -36 
Doc No D-17.029  
[Eikelboom 2006] Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of 
bleeding on prognosis in patients with acute coronary syndromes. Circulation 
2006;114:774â€“82. 
[Fox 2008] Fox KA, Anderson FA Jr, Goodman SG, Steg PG, Pi[INVESTIGATOR_26672] K, Quill A, et al. 
Time cours
e of events in acute coronary syndromes: implications for clinical 
practice from the GRACE registry. Nat. Clin . Pract. Cardiovasc. Med. 2008 Jul 29; 
5(9), 580â€“589. 
[Gaglia  2011] Gaglia MA, T orguson R, Pakala R, Xue Z, Sardi G, Suddath WO, et al. 
Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP -P platelet reactivity assays following percutaneous coronary intervention. 
J Interv Cardiol. 2011 Dec; 24(6):529â€“34. 
[Garofalo  2012] Garofalo D, Gre
 y C, Lee M, Exeter D, Kerr AJ Pre -hospi[INVESTIGATOR_400387]: PREDICT CVD -18. N Z Med J. 2012;125:12â€“22. 
[Gremmel  2009] Gremmel T, St einer S, Seidinger D, Koppensteiner R, Panzer S, Kopp 
CW. Comparison of methods to evaluate clopi[INVESTIGATOR_7745] -mediated platelet inhibition 
after percutaneous intervention with stent implantation. Thromb Haemost. 2009 Feb; 101(2):333â€“9. 
[Gremmet  2015] Gremmel T, Koppe
 nsteiner R, Panzer S. Comparison of Aggregometry 
with Flow Cytometry for the Assessment of AgonistsÂ´ -Induced Platelet Reactivity 
in Patients on Dual Antiplatelet Therapy. PLoS One. 2015 Jun 9; 10(6):e0129666. 
[Gurbel 2003] Gurbel PA, Bliden KP, Hiatt BL, O â€™Connor CM. Clopi[INVESTIGATOR_7745] f or coronary 
stenting: re sponse variability, drug resistance, and the effect of pretreatment platelet 
reactivity. Circulation 2003; 107:2908â€“13. 
[Gurbel 2009] Gurbel PA, Bliden KP, Butler K, Tantry US, Gescheff T, Wei C, et al. 
Randomized double -blind asse
ssment of the ONSET and O FFSET of the 
antiplatelet effects of ticagrelor versus clopi[INVESTIGATOR_104883]: the ONSET/OFFSET study. Circulation 2009; 120(25):2577â€“85. 
[Husted  2011] Husted S. Evaluat
 ing the risk- benefit profile of the direct- acting P2Y(12) 
inhibitor ticagrelor in acute coronary syndromes. Postgrad Med 2011;123:79â€“90. 
[Levine 2016] Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery By[CONTACT_400435] -[ADDRESS_504738] 2017, pa ge 82/[ADDRESS_504739] 2017 -003332 -36 
Doc No D-17.029  
Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the 
Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST -Elevation Myocardial Infarct ion, 
2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on 
Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation. 2016 Sep 6; 134(10):e123â€“55 
[Matetzky  2004] Matetzky S, S
 henkman B, Guetta V, Shechter M, Beinart R, 
Goldenberg I, et al. Clopi[INVESTIGATOR_400388]. Circulation 2004; 109:3171â€“5. 
[Michelson  2009] Alan D. Michels
 on. Methods for the measurement of platelet function. 
AJC online 2009; 103. 
[Michelson  2010] Michelson AD. A ntiplatelet therapi[INVESTIGATOR_400389]. Nat Rev Drug Discov 2 010;9:154â€“69. 
[Montalescot  2014] Montalescot G, van  â€™t  Hof A, Lapostolle F, Silvain J, Lassen JF, 
Bolognese L, et al. Prehospi[INVESTIGATOR_400390] -Segment Elevation Myocardial 
Infarction. N Engl J Med 2014; 371:1016â€“1027. 
[Nabel  2012] Nabel EG, Bra unwald E. A tale of coronary artery disease and myocardial 
infar ction. N Engl J Med. 2012; 366:54â€“63. 
[Oâ€™Gara 2013] O â€™Gara PT, Kushner F G, Ascheim DD, Casey DE Jr, Chung MK, de 
Lemos JA, et al. ACCF/AHA guideline for the management of ST -elevation 
myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 61 (4) :e78â€“140. 
[Prasugrel
Â® SmPC] PrasugrelÂ® Summary of Product Characteristics. Daiichi Sankyo 
Europe GmbH. December 2015. 
[Roffi  2016] Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 
[ADDRESS_504740] -segment elevation: Task Force for the 
Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST -Segment Elevation of the European Society of Cardiology (ESC). Eur 
Heart J . 2016; 37(3):267â€“315. 
ACT -[ADDRESS_504741] 2017, pa ge 83/[ADDRESS_504742] 2017 -003332 -36 
Doc No D-17.029  
[Savonitto 2017] Savonitto S, De Luca G, Goldstein P, van tâ€™ Hof A, Zeymer U, 
Morici  N, et al. Antithrombotic therapy before, during and after emergency 
angioplasty for ST elevation myocardial infarction. Eur Heart J Acute Cardiovasc 
Care 2017; 6(2):173â€“190 
[Steg  2012] Steg PG, James S K, Atar D, Badano LP, BlÃ¶mstrom -Lundgvist C, Borger 
MA, et al. ESC Guidelines for the management of acute myocardial infarction in 
patients presenting with ST -segment elevation. Eur Heart J. 2012; 33(20):2569â€“619 
[TicagrelorÂ® SmPC] TicagrelorÂ® Summary of Product Characteristics. [COMPANY_008] AB. 
September 2016. 
[Tubaro 2011] Tubaro M, Danchin N, Goldstein P, Filippatos G, Hasin Y , Heras M, et al. 
Pre-hospi[INVESTIGATOR_400391]. A scientific statement of the Working 
Group Acute Cardiac Care of the European Society of Cardiolog y. Acute Card Care 
2011; 13(2):56â€“67 
[van Giezen  2009] van Giezen JJ, Berntsson P, Zachrisson H, Bjorkman JA. Comparison 
of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic 
and bleeding effects in rat and dog models of thrombosis/hemostasis. Thromb Res 2009;124:565â€“71. 
[Varenhorst 2009] Varenhorst C, James S, Erlinge D, Braun OO, Brandt JT, Winters KJ, 
et al. Assessment 
of P2Y(12) inhibition with the point -of-c are device VerifyNow 
P2Y12 in patients treated with prasugrel or clopi[INVESTIGATOR_400392]. Am Heart J. 2009; 157(3):562.e1â€“9. 
[Wallentin  2009] Wallentin L, Be
 cker RC, Budaj A, Cannon CP, Emanuelsson H, 
Held  C, et al. Ticagrelor versus clopid ogrel in patients with acute coronary 
syndromes. N Engl J Med 2009;361:1045â€“57. 
[Wang  2010] Wang L, Wang X, C hen F. Clopi[INVESTIGATOR_400393] -
term thrombotic events in patients implanted with drug -eluting stents. Drugs in 
R&D 2010; 10:219â€“24. 
[Wiviott 2007] Wiviott SD, Braunwald E, McCabe CH, Montalesco G, Ruzyllo, 
G
ottlieb  S, et al. Prasugrel versus clopi[INVESTIGATOR_400394]. N Engl J Med 2007;357:2001â€“15. 